Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Gynecology

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 642 articles:
HTML format
Text format



Single Articles


    January 2018
  1. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Retroperitoneal lymphadenectomy for ovarian cancer with double inferior vena cava.
    Gynecol Oncol. 2018 Jan 5. pii: S0090-8258(17)31619.
    PubMed     Text format    


  2. MUKERJI B, Baptiste C, Chen L, Tergas AI, et al
    Racial disparities in young women with endometrial cancer.
    Gynecol Oncol. 2018 Jan 4. pii: S0090-8258(17)31623.
    PubMed     Text format     Abstract available


    December 2017
  3. TOUHAMI O, Gregoire J, Renaud MC, Sebastianelli A, et al
    The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia.
    Gynecol Oncol. 2017 Dec 28. pii: S0090-8258(17)31617.
    PubMed     Text format     Abstract available


  4. SOISSON S, Ganz PA, Gaffney D, Rowe K, et al
    Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study.
    Gynecol Oncol. 2017 Dec 27. pii: S0090-8258(17)31616.
    PubMed     Text format     Abstract available


  5. XIANG L, Jiang W, Ye S, He T, et al
    ERBB2 mutation: A promising target in non-squamous cervical cancer.
    Gynecol Oncol. 2017 Dec 23. pii: S0090-8258(17)31614.
    PubMed     Text format     Abstract available


  6. SUD S, Holmes J, Eblan M, Chen R, et al
    Clinical characteristics associated with racial disparities in endometrial cancer outcomes: A surveillance, epidemiology and end results analysis.
    Gynecol Oncol. 2017 Dec 21. pii: S0090-8258(17)31607.
    PubMed     Text format     Abstract available


  7. GEPPERT B, Lonnerfors C, Bollino M, Persson J, et al
    Sentinel lymph node biopsy in endometrial cancer-Feasibility, safety and lymphatic complications.
    Gynecol Oncol. 2017 Dec 20. pii: S0090-8258(17)31602.
    PubMed     Text format     Abstract available


  8. TRAN AQ, Erim DO, Sullivan SA, Cole AL, et al
    Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
    Gynecol Oncol. 2017 Dec 19. pii: S0090-8258(17)31598.
    PubMed     Text format     Abstract available


  9. FORNALIK H, Fornalik N
    Robotic hysterectomy and pelvic lymphadenectomy without Trendelenburg position (BMI 36).
    Gynecol Oncol. 2017 Dec 19. pii: S0090-8258(17)31549.
    PubMed     Text format    


  10. LEE J, Lin JB, Chang CL, Sun FJ, et al
    Impact of para-aortic recurrence risk-guided intensity-modulated radiotherapy in locally advanced cervical cancer with positive pelvic lymph nodes.
    Gynecol Oncol. 2017 Dec 18. pii: S0090-8258(17)31550.
    PubMed     Text format     Abstract available


  11. MIAO M, Deng G, Luo S, Zhou J, et al
    A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31596.
    PubMed     Text format     Abstract available


  12. MATSUO K, Ross MS, Im DD, Klobocista MM, et al
    Significance of venous thromboembolism in women with uterine carcinosarcoma.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31546.
    PubMed     Text format     Abstract available


  13. BRAGA A, Campos V, Filho JR, Lin LH, et al
    Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma?
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31554.
    PubMed     Text format     Abstract available


  14. BERNARDS SS, Pennington KP, Harrell MI, Agnew KJ, et al
    Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31551.
    PubMed     Text format     Abstract available


  15. KIM SI, Lee JW, Lee M, Kim HS, et al
    Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31552.
    PubMed     Text format     Abstract available


  16. COYLE C, Short D, Jackson L, Sebire NJ, et al
    What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31555.
    PubMed     Text format     Abstract available


  17. BIZZARRI N, Ghirardi V, Kucukmetin A
    Indocyanine green-assisted parametrial dissection during type C1 radical hysterectomy after sentinel lymph node biopsy in early stage cervical cancer.
    Gynecol Oncol. 2017 Dec 6. pii: S0090-8258(17)31496.
    PubMed     Text format     Abstract available


  18. WALLACE S, Hanson KT, Dowdy SC, Habermann EB, et al
    Impact of surgical approach and patient factors on Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey scoring in gynecologic surgery.
    Gynecol Oncol. 2017 Dec 5. pii: S0090-8258(17)31525.
    PubMed     Text format     Abstract available


  19. SMITH D, Stewart CJR, Clarke EM, Lose F, et al
    ER and PR expression and survival after endometrial cancer.
    Gynecol Oncol. 2017 Dec 4. pii: S0090-8258(17)31537.
    PubMed     Text format     Abstract available


  20. WORLEY MJ JR, Elias KM, Horowitz NS, Quade BJ, et al
    Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute.
    Gynecol Oncol. 2017 Dec 4. pii: S0090-8258(17)31539.
    PubMed     Text format     Abstract available


  21. ANNUNZIATA CM, Kohn EC
    Clinical trials in gynecologic oncology: Past, present, and future.
    Gynecol Oncol. 2017 Dec 3. pii: S0090-8258(17)31536.
    PubMed     Text format     Abstract available


  22. URBAN RR, He H, Alfonso R, Hardesty MM, et al
    The end of life costs for Medicare patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Dec 3. pii: S0090-8258(17)31533.
    PubMed     Text format     Abstract available


  23. WEN KC, Sung PL, Chou YT, Pan CM, et al
    The role of EpCAM in tumor progression and the clinical prognosis of endometrial carcinoma.
    Gynecol Oncol. 2017 Dec 2. pii: S0090-8258(17)31543.
    PubMed     Text format     Abstract available


  24. AVIKI EM, Abu-Rustum NR
    A call to standardize our approach to fertility-sparing surgery in patients with gynecologic cancers.
    Gynecol Oncol. 2017;147:491-492.
    PubMed     Text format    


  25. BITLER BG, Watson ZL, Wheeler LJ, Behbakht K, et al
    PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
    Gynecol Oncol. 2017;147:695-704.
    PubMed     Text format     Abstract available


  26. NOMURA H, Nagashima M, Aoki Y, Takeshima N, et al
    Resection of the inferior pubic ramus to completely remove locally advance adenoid cystic carcinoma of Bartholin's gland.
    Gynecol Oncol. 2017;147:723-724.
    PubMed     Text format     Abstract available


  27. PEI X, Xiang L, Ye S, He T, et al
    Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix.
    Gynecol Oncol. 2017;147:589-596.
    PubMed     Text format     Abstract available


  28. KUMAR A, Hurtt CC, Cliby WA, Martin JR, et al
    Concomitant venous thromboembolism at the time of primary EOC diagnosis: Perioperative outcomes and survival analyses.
    Gynecol Oncol. 2017;147:514-520.
    PubMed     Text format     Abstract available


  29. REISER E, Aust S, Seebacher V, Reinthaller A, et al
    Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses.
    Gynecol Oncol. 2017;147:690-694.
    PubMed     Text format     Abstract available


  30. CYBULSKA P, Goss C, Tew WP, Parameswaran R, et al
    Corrigendum to "Indications for and complications of transfusion and the management of gynecologic malignancies" [Gynecol. Oncol. 146 (2017) 416-426].
    Gynecol Oncol. 2017 Dec 1. pii: S0090-8258(17)31540.
    PubMed     Text format    


  31. MAHANTSHETTY U, Teni T, Naga P, Hotwani C, et al
    Impact of HPV 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy - A prospective observational study.
    Gynecol Oncol. 2017 Dec 1. pii: S0090-8258(17)31544.
    PubMed     Text format     Abstract available


  32. LI J, Li S, Yu H, Wang J, et al
    The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: A network meta-analysis.
    Gynecol Oncol. 2017 Dec 1. pii: S0090-8258(17)31541.
    PubMed     Text format     Abstract available


    November 2017
  33. HAMILTON CA, Miller A, Casablanca Y, Horowitz NS, et al
    Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.
    Gynecol Oncol. 2017 Nov 28. pii: S0090-8258(17)31528.
    PubMed     Text format     Abstract available


  34. ZHU J, Chen Z, Yong L
    Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer.
    Gynecol Oncol. 2017 Nov 27. pii: S0090-8258(17)31538.
    PubMed     Text format     Abstract available


  35. KITSON SJ, Lindsay J, Sivalingam VN, Lunt M, et al
    The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study.
    Gynecol Oncol. 2017 Nov 24. pii: S0090-8258(17)31529.
    PubMed     Text format     Abstract available


  36. MURALI R, Grisham RN, Soslow RA
    The roles of pathology in targeted therapy of women with gynecologic cancers.
    Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31530.
    PubMed     Text format     Abstract available


  37. MOSS HA, Havrilesky LJ
    The use of patient-reported outcome tools in Gynecologic Oncology research, clinical practice, and value-based care.
    Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31507.
    PubMed     Text format     Abstract available


  38. GULERIA S, Jensen A, Kjaer SK
    Risk of borderline ovarian tumors among women with benign ovarian tumors: A cohort study.
    Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31534.
    PubMed     Text format     Abstract available


  39. HOROWITZ NS, Larry Maxwell G, Miller A, Hamilton CA, et al
    Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.
    Gynecol Oncol. 2017 Nov 22. pii: S0090-8258(17)31371.
    PubMed     Text format     Abstract available


  40. LEE YJ, Chung YS, Lee JY, Nam EJ, et al
    Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Nov 21. pii: S0090-8258(17)31532.
    PubMed     Text format     Abstract available


  41. TOZZI R, Casarin J, Garruto-Campanile R, Majd HS, et al
    Morbidity and reversal rate of ileostomy after bowel resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer.
    Gynecol Oncol. 2017 Nov 20. pii: S0090-8258(17)31527.
    PubMed     Text format     Abstract available


  42. HEINZELMANN-SCHWARZ V, Knipprath Meszaros A, Stadlmann S, Jacob F, et al
    Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
    Gynecol Oncol. 2017 Nov 17. pii: S0090-8258(17)31458.
    PubMed     Text format     Abstract available


  43. CHAMPER M, Huang Y, Hou JY, Tergas AI, et al
    Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.
    Gynecol Oncol. 2017 Nov 15. pii: S0090-8258(17)31504.
    PubMed     Text format     Abstract available


  44. CHOLLI P, Bradford L, Manga S, Nulah K, et al
    Screening for cervical cancer among HIV-positive and HIV-negative women in Cameroon using simultaneous co-testing with careHPV DNA testing and visual inspection enhanced by digital cervicography: Findings of initial screening and one-year follow-up.
    Gynecol Oncol. 2017 Nov 15. pii: S0090-8258(17)31497.
    PubMed     Text format     Abstract available


  45. CHONG GO, Lee YH, Han HS, Lee HJ, et al
    Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer.
    Gynecol Oncol. 2017 Nov 15. pii: S0090-8258(17)31498.
    PubMed     Text format     Abstract available


  46. SHISLER R, Sinnott JA, Wang V, Hebert C, et al
    Life after endometrial cancer: A systematic review of patient-reported outcomes.
    Gynecol Oncol. 2017 Nov 14. pii: S0090-8258(17)31503.
    PubMed     Text format     Abstract available


  47. TAKIUCHI T, Blake EA, Matsuo K, Sood AK, et al
    Aspirin use and endometrial cancer risk and survival.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31448.
    PubMed     Text format     Abstract available


  48. SHAH JS, Gard GB, Yang J, Maidens J, et al
    Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31500.
    PubMed     Text format     Abstract available


  49. COSGROVE CM, Tritchler DL, Cohn DE, Mutch DG, et al
    An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31459.
    PubMed     Text format     Abstract available


  50. TIMMERMANS M, Schuurman MS, Ho VKY, Massuger LF, et al
    Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery.
    Gynecol Oncol. 2017 Nov 9. pii: S0090-8258(17)31505.
    PubMed     Text format     Abstract available


  51. MERT I, Kumar A, Sheedy SP, Weaver AL, et al
    Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival.
    Gynecol Oncol. 2017 Nov 9. pii: S0090-8258(17)31446.
    PubMed     Text format     Abstract available


  52. NIETO K, Adams W, Pham N, Block AM, et al
    Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database.
    Gynecol Oncol. 2017 Nov 9. pii: S0090-8258(17)31506.
    PubMed     Text format     Abstract available


  53. HOPPENOT C, Eckert MA, Tienda SM, Lengyel E, et al
    Who are the long-term survivors of high grade serous ovarian cancer?
    Gynecol Oncol. 2017 Nov 8. pii: S0090-8258(17)31454.
    PubMed     Text format     Abstract available


  54. HINCHCLIFF E, Melamed A, Bregar A, Diver E, et al
    Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
    Gynecol Oncol. 2017 Nov 8. pii: S0090-8258(17)31460.
    PubMed     Text format     Abstract available


  55. SPAANS VM, Nyoman Bayu Mahendra I, Purwoto G, Trietsch MD, et al
    The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
    Gynecol Oncol. 2017 Nov 4. pii: S0090-8258(17)31369.
    PubMed     Text format     Abstract available


  56. ISHIKAWA M, Kasamatsu T, Tsuda H, Fukunaga M, et al
    Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study.
    Gynecol Oncol. 2017 Nov 4. pii: S0090-8258(17)31449.
    PubMed     Text format     Abstract available


  57. CHAN JK, Kapp DS
    Clear Cell Ovarian Cancer: Optimum Management and Prognosis Remain Hazy.
    Gynecol Oncol. 2017;147:237-239.
    PubMed     Text format    


  58. ALTMAN AD, McGee J, May T, Lane K, et al
    Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study.
    Gynecol Oncol. 2017;147:257-261.
    PubMed     Text format     Abstract available


    October 2017
  59. FONNES T, Berg HF, Bredholt T, Edqvist PD, et al
    Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
    Gynecol Oncol. 2017 Oct 30. pii: S0090-8258(17)31447.
    PubMed     Text format     Abstract available


  60. MAESTA I, Nitecki R, Horowitz NS, Goldstein DP, et al
    Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
    Gynecol Oncol. 2017 Oct 29. pii: S0090-8258(17)31450.
    PubMed     Text format     Abstract available


  61. NING MS, Ahobila V, Jhingran A, Stecklein SR, et al
    Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer.
    Gynecol Oncol. 2017 Oct 28. pii: S0090-8258(17)31420.
    PubMed     Text format     Abstract available


  62. LEE JH, Lee SW, Kim JR, Kim YS, et al
    Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01.
    Gynecol Oncol. 2017 Oct 27. pii: S0090-8258(17)31360.
    PubMed     Text format     Abstract available


  63. CHENG H, Peng J, Yang Z, Zhang G, et al
    Prognostic significance of lymphadenectomyin malignant ovarian sex cord stromal tumor: A retrospective cohort study and meta-analysis.
    Gynecol Oncol. 2017 Oct 26. pii: S0090-8258(17)31444.
    PubMed     Text format     Abstract available


  64. RONCOLATO FT, Berton-Rigaud D, O'Connell R, Lanceley A, et al
    Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
    Gynecol Oncol. 2017 Oct 26. pii: S0090-8258(17)31422.
    PubMed     Text format     Abstract available


  65. LIN DI, Chudnovsky Y, Duggan B, Zajchowski D, et al
    Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
    Gynecol Oncol. 2017 Oct 25. pii: S0090-8258(17)31355.
    PubMed     Text format     Abstract available


  66. SHALOWITZ DI, Nivasch E, Burger RA, Schapira MM, et al
    Are patients willing to travel for better ovarian cancer care?
    Gynecol Oncol. 2017 Oct 24. pii: S0090-8258(17)31421.
    PubMed     Text format     Abstract available


  67. YI Y, Tsai SH, Cheng JC, Wang EY, et al
    APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner.
    Gynecol Oncol. 2017 Oct 24. pii: S0090-8258(17)31419.
    PubMed     Text format     Abstract available


  68. LAAN JJ, van Lonkhuijzen LRCW, van Os RM, Tytgat KM, et al
    Socioeconomic status as an independent risk factor for severe late bowel toxicity after primary radiotherapy for cervical cancer.
    Gynecol Oncol. 2017 Oct 23. pii: S0090-8258(17)31416.
    PubMed     Text format     Abstract available


  69. MATSUO K, Ross MS, Yunokawa M, Johnson MS, et al
    Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma.
    Gynecol Oncol. 2017 Oct 19. pii: S0090-8258(17)31368.
    PubMed     Text format     Abstract available


  70. TANNER E, Puechl A, Levinson K, Havrilesky LJ, et al
    Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer.
    Gynecol Oncol. 2017 Oct 19. pii: S0090-8258(17)31423.
    PubMed     Text format     Abstract available


  71. YAMAMOTO K, Nagao S, Suzuki K, Kogiku A, et al
    Pelvic fractures after definitive and postoperative radiotherapy for cervical cancer: A retrospective analysis of risk factors.
    Gynecol Oncol. 2017 Oct 18. pii: S0090-8258(17)31359.
    PubMed     Text format     Abstract available


  72. ARIMA R, Hautakoski A, Marttila M, Arffman M, et al
    Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication.
    Gynecol Oncol. 2017 Oct 17. pii: S0090-8258(17)31417.
    PubMed     Text format     Abstract available


  73. JONES MR, Kamara D, Karlan BY, Pharoah PDP, et al
    Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction.
    Gynecol Oncol. 2017 Oct 17. pii: S0090-8258(17)31361.
    PubMed     Text format     Abstract available


  74. CHEN BJ, Byrne FL, Takenaka K, Modesitt SC, et al
    Transcriptome landscape of long intergenic non-coding RNAs in endometrial cancer.
    Gynecol Oncol. 2017 Oct 16. pii: S0090-8258(17)31367.
    PubMed     Text format     Abstract available


  75. SCHULTZ KAP, Harris AK, Finch M, Dehner LP, et al
    DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry.
    Gynecol Oncol. 2017 Oct 13. pii: S0090-8258(17)31358.
    PubMed     Text format     Abstract available


  76. DOCKERY LE, Tew WP, Ding K, Moore KN, et al
    Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Oct 13. pii: S0090-8258(17)31364.
    PubMed     Text format     Abstract available


  77. POZZAR RA, Berry DL
    Patient-centered research priorities in ovarian cancer: A systematic review of potential determinants of guideline care.
    Gynecol Oncol. 2017 Oct 10. pii: S0090-8258(17)31365.
    PubMed     Text format     Abstract available


  78. DE LIMA MAP, Neto PJN, Lima LPM, Goncalves Junior J, et al
    Association between Epstein-Barr virus (EBV) and cervical carcinoma: A meta-analysis.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31366.
    PubMed     Text format     Abstract available


  79. NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
    Fertility-preserving surgery for advanced stage ovarian germ cell tumors.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31370.
    PubMed     Text format     Abstract available


  80. XIA Z, Cochrane DR, Anglesio MS, Wang YK, et al
    LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31356.
    PubMed     Text format     Abstract available


  81. BUDA A, Di Martino G, Restaino S, De Ponti E, et al
    The impact on survival of two different staging strategies in apparent early stage endometrial cancer comparing sentinel lymph nodes mapping algorithm and selective lymphadenectomy: An Italian retrospective analysis of two reference centers.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31357.
    PubMed     Text format     Abstract available


  82. PEPIN K, Bregar A, Davis M, Melamed A, et al
    Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
    Gynecol Oncol. 2017 Oct 4. pii: S0090-8258(17)31352.
    PubMed     Text format     Abstract available


  83. MATSUO K, Machida H, Frimer M, Marcus JZ, et al
    Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer.
    Gynecol Oncol. 2017 Oct 3. pii: S0090-8258(17)31351.
    PubMed     Text format     Abstract available


  84. SINGH S, Swarer K, Resnick K
    Longer operative time is associated with increased post-operative complications in patients undergoing minimally-invasive surgery for endometrial cancer.
    Gynecol Oncol. 2017 Oct 2. pii: S0090-8258(17)31348.
    PubMed     Text format     Abstract available


  85. HENSLEY ML
    Difficult Choices in Stage I Uterine Leiomyosarcoma- it's okay to "stand there".
    Gynecol Oncol. 2017;147:1-2.
    PubMed     Text format    


  86. POLTERAUER S, Schwameis R, Grimm C, Macuks R, et al
    Prognostic value of lymph node ratio and number of positive inguinal nodes in patients with vulvar cancer.
    Gynecol Oncol. 2017;147:92-97.
    PubMed     Text format     Abstract available


    September 2017
  87. DEVOR EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, et al
    Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Sep 29. pii: S0090-8258(17)31349.
    PubMed     Text format     Abstract available


  88. DUCIE JA, Eriksson AGZ, Ali N, McGree ME, et al
    Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31354.
    PubMed     Text format     Abstract available


  89. PHILP L, Covens A, Vicus D, Kupets R, et al
    Feasibility and safety of same-day discharge after laparoscopic radical hysterectomy for cervix cancer.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31350.
    PubMed     Text format     Abstract available


  90. QIU C, Lu N, Wang X, Zhang Q, et al
    Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31353.
    PubMed     Text format     Abstract available


  91. TORRES D, Kumar A, Wallace SK, Bakkum-Gamez JN, et al
    Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer.
    Gynecol Oncol. 2017 Sep 27. pii: S0090-8258(17)31345.
    PubMed     Text format     Abstract available


  92. COSGROVE CM, Cohn DE, Goodfellow PJ
    Primum non nocere: Are we ready for POLE testing in endometrial cancer?
    Gynecol Oncol. 2017 Sep 22. pii: S0090-8258(17)31339.
    PubMed     Text format    


  93. CYBULSKA P, Schiavone MB, Sawyer B, Gardner GJ, et al
    Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer.
    Gynecol Oncol. 2017 Sep 22. pii: S0090-8258(17)31302.
    PubMed     Text format     Abstract available


  94. NELSON G, Dowdy SC, Lasala J, Mena G, et al
    Enhanced recovery after surgery (ERAS(R)) in gynecologic oncology - Practical considerations for program development.
    Gynecol Oncol. 2017 Sep 22. pii: S0090-8258(17)31347.
    PubMed     Text format    


  95. MAKKONEN P, Heinavaara S, Sarkeala T, Anttila A, et al
    Impact of organized and opportunistic Pap testing on the risk of cervical cancer in young women - A case-control study from Finland.
    Gynecol Oncol. 2017 Sep 21. pii: S0090-8258(17)31335.
    PubMed     Text format     Abstract available


  96. TOUHAMI O, Gregoire J, Renaud MC, Sebastianelli A, et al
    Performance of sentinel lymph node (SLN) mapping in high-risk endometrial cancer.
    Gynecol Oncol. 2017 Sep 21. pii: S0090-8258(17)31338.
    PubMed     Text format     Abstract available


  97. SHAH JS, Guerra R, Bodurka DC, Sun CC, et al
    Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of Society of Gynecologic Oncology members.
    Gynecol Oncol. 2017 Sep 21. pii: S0090-8258(17)31343.
    PubMed     Text format     Abstract available


  98. BARBER EL, Rossi EC, Gehrig PA
    Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?
    Gynecol Oncol. 2017 Sep 20. pii: S0090-8258(17)31340.
    PubMed     Text format     Abstract available


  99. DO JH, Choi KH, Ahn JS, Jeon JY, et al
    Effects of a complex rehabilitation program on edema status, physical function, and quality of life in lower-limb lymphedema after gynecological cancer surgery.
    Gynecol Oncol. 2017 Sep 20. pii: S0090-8258(17)31272.
    PubMed     Text format     Abstract available


  100. RUSTIN G, Vergote I, Micha JP, Duska LR, et al
    A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31264.
    PubMed     Text format     Abstract available


  101. MOORE KN, Tritchler D, Kaufman KM, Lankes H, et al
    Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31261.
    PubMed     Text format     Abstract available


  102. LEE SW, Lee SH, Kim J, Kim YS, et al
    Magnetic resonance imaging during definitive chemoradiotherapy can predict tumor recurrence and patient survival in locally advanced cervical cancer: A multi-institutional retrospective analysis of KROG 16-01.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31265.
    PubMed     Text format     Abstract available


  103. TANGEN IL, Veneris JT, Halle MK, Werner HM, et al
    Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions.
    Gynecol Oncol. 2017 Sep 16. pii: S0090-8258(17)31337.
    PubMed     Text format     Abstract available


  104. DANTAS PRS, Maesta I, Filho JR, Junior JA, et al
    Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors?
    Gynecol Oncol. 2017 Sep 16. pii: S0090-8258(17)31310.
    PubMed     Text format     Abstract available


  105. RAUH LA, Pannone AF, Cantrell LA
    Hormone replacement therapy after treatment for cervical cancer: Are we adhering to standard of care?
    Gynecol Oncol. 2017 Sep 16. pii: S0090-8258(17)31333.
    PubMed     Text format     Abstract available


  106. GEBHARDT B, Gill B, Glaser S, Kim H, et al
    Image-guided tandem and cylinder brachytherapy as monotherapy for definitive treatment of inoperable endometrial carcinoma.
    Gynecol Oncol. 2017 Sep 15. pii: S0090-8258(17)31309.
    PubMed     Text format     Abstract available


  107. AZAIS H, Ghesquiere L, Petitnicolas C, Borghesi Y, et al
    Pretherapeutic staging of locally advanced cervical cancer: Inframesenteric paraaortic lymphadenectomy accuracy to detect paraaortic metastases in comparison with infrarenal paraaortic lymphadenectomy.
    Gynecol Oncol. 2017 Sep 14. pii: S0090-8258(17)31334.
    PubMed     Text format     Abstract available


  108. BINDER PS, Kuroki LM, Zhao P, Cusworth S, et al
    Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancer.
    Gynecol Oncol. 2017 Sep 12. pii: S0090-8258(17)31269.
    PubMed     Text format     Abstract available


  109. LILYQUIST J, LaDuca H, Polley E, Davis BT, et al
    Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls.
    Gynecol Oncol. 2017 Sep 7. pii: S0090-8258(17)31268.
    PubMed     Text format     Abstract available


  110. PISU M, Kenzik KM, Rim SH, Funkhouser EM, et al
    Values and worries of ovarian cancer patients.
    Gynecol Oncol. 2017 Sep 6. pii: S0090-8258(17)31267.
    PubMed     Text format     Abstract available


  111. COWAN RA, Tseng J, Murthy V, Srivastava R, et al
    Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
    Gynecol Oncol. 2017 Sep 6. pii: S0090-8258(17)31270.
    PubMed     Text format     Abstract available


  112. SCHLUMBRECHT M, Baeker Bispo JA, Balise RR, Huang M, et al
    Variation in type II endometrial cancer risk by Hispanic subpopulation: An exploratory analysis.
    Gynecol Oncol. 2017 Sep 6. pii: S0090-8258(17)31271.
    PubMed     Text format     Abstract available


  113. OZA AM, Tinker AV, Oaknin A, Shapira-Frommer R, et al
    Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
    Gynecol Oncol. 2017 Sep 4. pii: S0090-8258(17)31260.
    PubMed     Text format     Abstract available


  114. HAVRILESKY LJ
    The costs of adding laparoscopy to the management of advanced stage epithelial ovarian cancer.
    Gynecol Oncol. 2017;146:441-442.
    PubMed     Text format    


  115. HUO D, Anderson D, Palmer JR, Herbst AL, et al
    Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up.
    Gynecol Oncol. 2017;146:566-571.
    PubMed     Text format     Abstract available


  116. POUWER AW, Hinten F, van der Velden J, Smolders RGV, et al
    Volume-controlled versus short drainage after inguinofemoral lymphadenectomy in vulvar cancer patients: A Dutch nationwide prospective study.
    Gynecol Oncol. 2017;146:580-587.
    PubMed     Text format     Abstract available


  117. RAO YJ, Chin RI, Hui C, Mutch DG, et al
    Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database.
    Gynecol Oncol. 2017;146:572-579.
    PubMed     Text format     Abstract available


  118. LOPEZ LABROUSSE MI, Frumovitz M, Guadalupe Patrono M, Ramirez PT, et al
    Sentinel lymph node mapping in minimally invasive surgery: Role of imaging with color-segmented fluorescence (CSF).
    Gynecol Oncol. 2017;146:676-677.
    PubMed     Text format     Abstract available


    August 2017
  119. CHEN KS, Berhane H, Gill BS, Olawaiye A, et al
    Outcomes of stage II endometrial cancer: The UPMC Hillman Cancer Center experience.
    Gynecol Oncol. 2017 Aug 30. pii: S0090-8258(17)31259.
    PubMed     Text format     Abstract available


  120. WANG X, Ivan M, Hawkins SM
    The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.
    Gynecol Oncol. 2017 Aug 30. pii: S0090-8258(17)31266.
    PubMed     Text format     Abstract available


  121. ZHU Z, Lou C, Zheng Z, Zhu R, et al
    ZFP403, a novel tumor suppressor, inhibits the proliferation and metastasis in ovarian cancer.
    Gynecol Oncol. 2017 Aug 30. pii: S0090-8258(17)31263.
    PubMed     Text format     Abstract available


  122. LAGO V, Domingo S, Matute L, Padilla P, et al
    Ghost ileostomy in advanced ovarian cancer.
    Gynecol Oncol. 2017 Aug 29. pii: S0090-8258(17)31255.
    PubMed     Text format    


  123. GOFF BA, Agnew K, Neradilek MB, Gray HJ, et al
    Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
    Gynecol Oncol. 2017 Aug 28. pii: S0090-8258(17)31258.
    PubMed     Text format     Abstract available


  124. DUAN H, Yan Z, Chen W, Wu Y, et al
    TET1 inhibits EMT of ovarian cancer cells through activating Wnt/beta-catenin signaling inhibitors DKK1 and SFRP2.
    Gynecol Oncol. 2017 Aug 26. pii: S0090-8258(17)31248.
    PubMed     Text format     Abstract available


  125. TAKAHASHI K, Sato N, Sugawara T, Kato A, et al
    Clinical characteristics of Lynch-like cases collaterally classified by Lynch syndrome identification strategy using universal screening in endometrial cancer.
    Gynecol Oncol. 2017 Aug 25. pii: S0090-8258(17)31254.
    PubMed     Text format     Abstract available


  126. UDAGER AM, Frisch NK, Hong LJ, Stasenko M, et al
    Gynecologic melanomas: A clinicopathologic and molecular analysis.
    Gynecol Oncol. 2017 Aug 24. pii: S0090-8258(17)31262.
    PubMed     Text format     Abstract available


  127. HERZOG TJ, Ison G, Alvarez RD, Balasubramaniam S, et al
    FDA ovarian cancer clinical trial endpoints workshop.
    Gynecol Oncol. 2017 Aug 24. pii: S0090-8258(17)31250.
    PubMed     Text format    


  128. MARTIN LP, Konner JA, Moore KN, Seward SM, et al
    Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRalpha-targeting antibody-drug conjugate mirvetuximab soravtansine.
    Gynecol Oncol. 2017 Aug 24. pii: S0090-8258(17)31253.
    PubMed     Text format     Abstract available


  129. HEIJKOOP ST, Nout RA, Quint S, Mens JWM, et al
    Dynamics of patient reported quality of life and symptoms in the acute phase of online adaptive external beam radiation therapy for locally advanced cervical cancer.
    Gynecol Oncol. 2017 Aug 19. pii: S0090-8258(17)31247.
    PubMed     Text format     Abstract available


  130. PEARL ML, Dong H, Zhao Q, Tulley S, et al
    iCTC drug resistance (CDR) Testing ex vivo for evaluation of available therapies to treat patients with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Aug 19. pii: S0090-8258(17)31256.
    PubMed     Text format     Abstract available


  131. JOHNATTY SE, Tan YY, Buchanan DD, Bowman M, et al
    Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling.
    Gynecol Oncol. 2017 Aug 16. pii: S0090-8258(17)31249.
    PubMed     Text format     Abstract available


  132. MELAMED A, Manning-Geist B, Bregar AJ, Diver EJ, et al
    Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Gynecol Oncol. 2017 Aug 16. pii: S0090-8258(17)31225.
    PubMed     Text format     Abstract available


  133. OLIVER KE, Brady WE, Birrer M, Gershenson DM, et al
    An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
    Gynecol Oncol. 2017 Aug 11. pii: S0090-8258(17)31226.
    PubMed     Text format     Abstract available


  134. GARCIA C, Lefkowits C, Pelkofski E, Blackhall L, et al
    Prospective screening with the validated Opioid Risk Tool demonstrates gynecologic oncology patients are at low risk for opioid misuse.
    Gynecol Oncol. 2017 Aug 11. pii: S0090-8258(17)31246.
    PubMed     Text format     Abstract available


  135. NASIOUDIS D, Chapman-Davis E, Frey MK, Caputo TA, et al
    Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base.
    Gynecol Oncol. 2017 Aug 10. pii: S0090-8258(17)31251.
    PubMed     Text format     Abstract available


  136. THAKER PH, Brady WE, Lankes HA, Odunsi K, et al
    A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary perito
    Gynecol Oncol. 2017 Aug 9. pii: S0090-8258(17)31186.
    PubMed     Text format     Abstract available


  137. TORGESON A, Boothe D, Poppe MM, Suneja G, et al
    Disparities in care for elderly women with endometrial cancer adversely effects survival.
    Gynecol Oncol. 2017 Aug 9. pii: S0090-8258(17)31227.
    PubMed     Text format     Abstract available


  138. TARNEY CM, Tian C, Wang G, Dubil EA, et al
    Impact of age at diagnosis on racial disparities in endometrial cancer patients.
    Gynecol Oncol. 2017 Aug 8. pii: S0090-8258(17)31185.
    PubMed     Text format     Abstract available


  139. FORTNER RT, Damms-Machado A, Kaaks R
    Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
    Gynecol Oncol. 2017 Aug 8. pii: S0090-8258(17)31178.
    PubMed     Text format     Abstract available


  140. SENTER L, O'Malley DM, Backes FJ, Copeland LJ, et al
    Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care.
    Gynecol Oncol. 2017 Aug 8. pii: S0090-8258(17)31182.
    PubMed     Text format     Abstract available


  141. KNAPP P, Bodnar L, Blachnio-Zabielska A, Swiderska M, et al
    Plasma and ovarian tissue sphingolipids profiling in patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Aug 8. pii: S0090-8258(17)31183.
    PubMed     Text format     Abstract available


  142. TATE S, Kato K, Nishikimi K, Matsuoka A, et al
    Survival and safety associated with aggressive surgery for stage III/IV epithelial ovarian cancer: A single institution observation study.
    Gynecol Oncol. 2017 Aug 8. pii: S0090-8258(17)31176.
    PubMed     Text format     Abstract available


  143. LINKOV F, Goughnour SL, Ma T, Xu Z, et al
    Changes in inflammatory endometrial cancer risk biomarkers in individuals undergoing surgical weight loss.
    Gynecol Oncol. 2017 Aug 7. pii: S0090-8258(17)31184.
    PubMed     Text format     Abstract available


  144. MULLEN MM, Divine LM, Porcelli BP, Wilkinson-Ryan I, et al
    The effect of a multidisciplinary palliative care initiative on end of life care in gynecologic oncology patients.
    Gynecol Oncol. 2017 Aug 4. pii: S0090-8258(17)31187.
    PubMed     Text format     Abstract available


  145. BOGANI G, Tagliabue E, Ditto A, Signorelli M, et al
    Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses.
    Gynecol Oncol. 2017 Aug 2. pii: S0090-8258(17)31179.
    PubMed     Text format     Abstract available


  146. CRIM A, Rowland M, Ruskin R, Dvorak J, et al
    Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
    Gynecol Oncol. 2017;146:268-272.
    PubMed     Text format     Abstract available


  147. PALISOUL ML, Mullen MM, Feldman R, Thaker PH, et al
    Identification of molecular targets in vulvar cancers.
    Gynecol Oncol. 2017;146:305-313.
    PubMed     Text format     Abstract available


  148. KASHOFER K, Regauer S
    Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy.
    Gynecol Oncol. 2017;146:314-318.
    PubMed     Text format     Abstract available


    July 2017
  149. CHOI C, Kim WY, Lee DH, Oh SS, et al
    Cytoreduction of bulky para-aortic lymphadenopathy from metastatic ovarian cancer.
    Gynecol Oncol. 2017 Jul 31. pii: S0090-8258(17)31173.
    PubMed     Text format    


  150. FLEMING ND, Coleman RL, Tung C, Westin SN, et al
    Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Jul 31. pii: S0090-8258(17)31177.
    PubMed     Text format     Abstract available


  151. FADER AN, Bergstrom J, Jernigan A, Tanner EJ 3rd, et al
    Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
    Gynecol Oncol. 2017 Jul 30. pii: S0090-8258(17)31167.
    PubMed     Text format     Abstract available


  152. HOGEN L, Brar H, Covens A, Bassiouny D, et al
    Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma?
    Gynecol Oncol. 2017 Jul 28. pii: S0090-8258(17)31168.
    PubMed     Text format     Abstract available


  153. MEIRELES CG, Pereira SA, Valadares LP, Rego DF, et al
    Effects of metformin on endometrial cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2017 Jul 28. pii: S0090-8258(17)31136.
    PubMed     Text format     Abstract available


  154. COHN DE, Sill MW, Walker JL, O'Malley D, et al
    Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin(R)) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Jul 27. pii: S0090-8258(17)31175.
    PubMed     Text format     Abstract available


  155. MILLER EM, Tymon-Rosario J, Xie X, Xue X, et al
    Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
    Gynecol Oncol. 2017 Jul 24. pii: S0090-8258(17)31169.
    PubMed     Text format     Abstract available


  156. PERSSON J, Geppert B, Lonnerfors C, Bollino M, et al
    Description of a reproducible anatomically based surgical algorithm for detection of pelvic sentinel lymph nodes in endometrial cancer.
    Gynecol Oncol. 2017 Jul 24. pii: S0090-8258(17)31170.
    PubMed     Text format     Abstract available


  157. LITTELL RD, Tucker LY, Raine-Bennett T, Palen TE, et al
    Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
    Gynecol Oncol. 2017 Jul 24. pii: S0090-8258(17)31139.
    PubMed     Text format     Abstract available


  158. PHIPPEN NT, Secord AA, Wolf S, Samsa G, et al
    Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.
    Gynecol Oncol. 2017 Jul 22. pii: S0090-8258(17)31138.
    PubMed     Text format     Abstract available


  159. ADAM JP, Boumedien F, Letarte N, Provencher D, et al
    Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
    Gynecol Oncol. 2017 Jul 21. pii: S0090-8258(17)31160.
    PubMed     Text format     Abstract available


  160. KOGAN L, Laskov I, Amajoud Z, Abitbol J, et al
    Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer.
    Gynecol Oncol. 2017 Jul 20. pii: S0090-8258(17)31174.
    PubMed     Text format     Abstract available


  161. KNIFIC T, Osredkar J, Smrkolj S, Tonin I, et al
    Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer.
    Gynecol Oncol. 2017 Jul 20. pii: S0090-8258(17)31171.
    PubMed     Text format     Abstract available


  162. SCHIAVONE MB, Moukarzel L, Leong K, Zhou QC, et al
    Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery.
    Gynecol Oncol. 2017 Jul 19. pii: S0090-8258(17)31027.
    PubMed     Text format     Abstract available


  163. KUMAR A, Langstraat CL, DeJong SR, McGree ME, et al
    Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer.
    Gynecol Oncol. 2017 Jul 19. pii: S0090-8258(17)31163.
    PubMed     Text format     Abstract available


  164. SCHWARTZ ZP, Frey MK, Philips S, Curtin JP, et al
    Endometrial cancer surveillance adherence reduces utilization and subsequent costs.
    Gynecol Oncol. 2017 Jul 19. pii: S0090-8258(17)30965.
    PubMed     Text format     Abstract available


  165. CHAN JK, Deng W, Higgins RV, Tewari KS, et al
    A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Jul 17. pii: S0090-8258(17)30889.
    PubMed     Text format     Abstract available


  166. KHATIB G, Guzel AB, Gulec UK, Vardar MA, et al
    A novel technique: Carbon dioxide gas-assisted total peritonectomy, diaphragm and intestinal meso stripping in open surgery for advanced ovarian cancer (Cukurova technique).
    Gynecol Oncol. 2017 Jul 15. pii: S0090-8258(17)31172.
    PubMed     Text format     Abstract available


  167. HOW J, Boldeanu I, Lau S, Salvador S, et al
    Unexpected locations of sentinel lymph nodes in endometrial cancer.
    Gynecol Oncol. 2017 Jul 14. pii: S0090-8258(17)31162.
    PubMed     Text format     Abstract available


  168. NASIOUDIS D, Chapman-Davis E, Frey MK, Caputo TA, et al
    Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB?
    Gynecol Oncol. 2017 Jul 14. pii: S0090-8258(17)31161.
    PubMed     Text format     Abstract available


  169. FALCONE F, Scambia G, Benedetti Panici P, Signorelli M, et al
    Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
    Gynecol Oncol. 2017 Jul 14. pii: S0090-8258(17)31025.
    PubMed     Text format     Abstract available


  170. DE AZEVEDO CRAS, Thuler LCS, de Mello MJG, de Oliveira Lima JT, et al
    Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer.
    Gynecol Oncol. 2017 Jul 11. pii: S0090-8258(17)31023.
    PubMed     Text format     Abstract available


  171. COSGROVE CM, Cohn DE, Hampel H, Frankel WL, et al
    Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
    Gynecol Oncol. 2017 Jul 11. pii: S0090-8258(17)30980.
    PubMed     Text format     Abstract available


  172. QIAN Y, Pollom EL, Nwachukwu C, Seiger K, et al
    Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma.
    Gynecol Oncol. 2017 Jul 11. pii: S0090-8258(17)31137.
    PubMed     Text format     Abstract available


  173. PALEARI L, Gandini S, Provinciali N, Puntoni M, et al
    Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis.
    Gynecol Oncol. 2017 Jul 10. pii: S0090-8258(17)30977.
    PubMed     Text format     Abstract available


  174. MENDERES G, Bonazzoli E, Bellone S, Altwerger G, et al
    Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
    Gynecol Oncol. 2017 Jul 10. pii: S0090-8258(17)31026.
    PubMed     Text format     Abstract available


  175. MOULTON LJ, Michener CM, Levinson K, Cobb L, et al
    Compliance with research standards within gynecologic oncology fellowship: A Gynecologic Oncology Fellowship Research Network (GOFRN) study.
    Gynecol Oncol. 2017 Jul 8. pii: S0090-8258(17)30975.
    PubMed     Text format     Abstract available


  176. KRISTELEIT R, Davidenko I, Shirinkin V, El-Khouly F, et al
    A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
    Gynecol Oncol. 2017 Jul 8. pii: S0090-8258(17)31022.
    PubMed     Text format     Abstract available


  177. YUAN X, Zhang J, Li D, Mao Y, et al
    Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2017 Jul 8. pii: S0090-8258(17)31024.
    PubMed     Text format     Abstract available


  178. GREENWADE MM, Moore KN, Gillen JM, Ding K, et al
    Factors influencing clinical trial enrollment among ovarian cancer patients.
    Gynecol Oncol. 2017 Jul 6. pii: S0090-8258(17)30976.
    PubMed     Text format     Abstract available


  179. ETHIER JL, Desautels DN, Amir E, MacKay H, et al
    Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis.
    Gynecol Oncol. 2017 Jul 6. pii: S0090-8258(17)30979.
    PubMed     Text format     Abstract available


  180. MATZ M, Coleman MP, Carreira H, Salmeron D, et al
    Erratum to "Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 396-404].
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30974.
    PubMed     Text format    


  181. SON JH, Chang SJ, Ryu HS
    Porta hepatis debulking procedures as part of primary cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30978.
    PubMed     Text format     Abstract available


  182. MATZ M, Coleman MP, Sant M, Chirlaque MD, et al
    Erratum to "The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 405-413].
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30973.
    PubMed     Text format    


  183. LENNOX GK, Covens A
    Management Of Early Stage Cervical Cancer: When Is Non-Randomized Data Good Enough?
    Gynecol Oncol. 2017;146:1-2.
    PubMed     Text format    


  184. SWANICK CW, Eifel PJ, Huo J, Meyer LA, et al
    Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with node-positive vulvar cancer.
    Gynecol Oncol. 2017;146:87-93.
    PubMed     Text format     Abstract available


  185. RAPHAELIS S, Mayer H, Ott S, Mueller MD, et al
    The impact of written information and counseling (WOMAN-PRO II Program) on symptom outcomes in women with vulvar neoplasia: A multicenter randomized controlled phase II study.
    Gynecol Oncol. 2017;146:114-122.
    PubMed     Text format     Abstract available


  186. MESERVE EEK, Mirkovic J, Conner JR, Yang E, et al
    Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study.
    Gynecol Oncol. 2017;146:69-73.
    PubMed     Text format     Abstract available


    June 2017
  187. KAWABATA A, Yanaihara N, Nagata C, Saito M, et al
    Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
    Gynecol Oncol. 2017 Jun 30. pii: S0090-8258(17)30968.
    PubMed     Text format     Abstract available


  188. PABALAN N, Kunjantarachot A, Ruangpratheep C, Jarjanazi H, et al
    Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2017 Jun 29. pii: S0090-8258(17)30957.
    PubMed     Text format     Abstract available


  189. SUN Z, Gilbert L, Ciampi A, Basso O, et al
    Recruitment challenges in clinical research: Survey of potential participants in a diagnostic study of ovarian cancer.
    Gynecol Oncol. 2017 Jun 27. pii: S0090-8258(17)30962.
    PubMed     Text format     Abstract available


  190. EGGEMANN H, Ignatov T, Burger E, Costa SD, et al
    Management of elderly women with endometrial cancer.
    Gynecol Oncol. 2017 Jun 27. pii: S0090-8258(17)30970.
    PubMed     Text format     Abstract available


  191. TURNER TB, Dilley SE, Smith HJ, Huh WK, et al
    The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis.
    Gynecol Oncol. 2017 Jun 24. pii: S0090-8258(17)30967.
    PubMed     Text format     Abstract available


  192. VIAU M, Renaud MC, Gregoire J, Sebastianelli A, et al
    Paraneoplastic syndromes associated with gynecological cancers: A systematic review.
    Gynecol Oncol. 2017 Jun 24. pii: S0090-8258(17)30966.
    PubMed     Text format     Abstract available


  193. HENSLEY ML, Patel SR, von Mehren M, Ganjoo K, et al
    Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
    Gynecol Oncol. 2017 Jun 23. pii: S0090-8258(17)30959.
    PubMed     Text format     Abstract available


  194. MELAMED A, Rauh-Hain JA, Schorge JO
    Clinical outcomes research in gynecologic oncology.
    Gynecol Oncol. 2017 Jun 23. pii: S0090-8258(17)30958.
    PubMed     Text format     Abstract available


  195. PROCTOR L, Pradhan M, Leung S, Cheng A, et al
    Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
    Gynecol Oncol. 2017 Jun 21. pii: S0090-8258(17)30961.
    PubMed     Text format     Abstract available


  196. VAN DE VRIE R, van Meurs HS, Rutten MJ, Naaktgeboren CA, et al
    Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer.
    Gynecol Oncol. 2017 Jun 20. pii: S0090-8258(17)30960.
    PubMed     Text format     Abstract available


  197. ARIMA R, Marttila M, Hautakoski A, Arffman M, et al
    Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes.
    Gynecol Oncol. 2017 Jun 20. pii: S0090-8258(17)30952.
    PubMed     Text format     Abstract available


  198. DOWDY SC, Nelson G
    Enhanced recovery in gynecologic oncology - A sea change in perioperative management.
    Gynecol Oncol. 2017 Jun 20. pii: S0090-8258(17)30956.
    PubMed     Text format    


  199. MOSS HA, Havrilesky LJ, Chino J
    Insurance coverage among women diagnosed with a gynecologic malignancy before and after implementation of the Affordable Care Act.
    Gynecol Oncol. 2017 Jun 19. pii: S0090-8258(17)30953.
    PubMed     Text format     Abstract available


  200. CUPPENS T, Depreeuw J, Annibali D, Thomas D, et al
    Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models.
    Gynecol Oncol. 2017 Jun 16. pii: S0090-8258(17)30900.
    PubMed     Text format     Abstract available


  201. DEL CARMEN MG, Rice LW
    Management of menopausal symptoms in women with gynecologic cancers.
    Gynecol Oncol. 2017 Jun 15. pii: S0090-8258(17)30954.
    PubMed     Text format     Abstract available


  202. SOOVARES P, Pasanen A, Butzow R, Lassus H, et al
    L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
    Gynecol Oncol. 2017 Jun 15. pii: S0090-8258(17)30939.
    PubMed     Text format     Abstract available


  203. MARTINELLI F, Ditto A, Signorelli M, Bogani G, et al
    Sentinel node mapping in endometrial cancer following Hysteroscopic injection of tracers: A single center evaluation over 200 cases.
    Gynecol Oncol. 2017 Jun 15. pii: S0090-8258(17)30955.
    PubMed     Text format     Abstract available


  204. HAYES SC, Janda M, Ward LC, Reul-Hirche H, et al
    Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors.
    Gynecol Oncol. 2017 Jun 14. pii: S0090-8258(17)30899.
    PubMed     Text format     Abstract available


  205. SZENDER JB, Emmons T, Belliotti S, Dickson D, et al
    Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.
    Gynecol Oncol. 2017 Jun 14. pii: S0090-8258(17)30937.
    PubMed     Text format     Abstract available


  206. BEDNAR EM, Oakley HD, Sun CC, Burke CC, et al
    A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
    Gynecol Oncol. 2017 Jun 10. pii: S0090-8258(17)30893.
    PubMed     Text format     Abstract available


  207. GRIMM C, Harter P, Alesina PF, Prader S, et al
    The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery.
    Gynecol Oncol. 2017 Jun 10. pii: S0090-8258(17)30936.
    PubMed     Text format     Abstract available


  208. CASTLE PE, Kinney WK, Cheung LC, Gage JC, et al
    Why does cervical cancer occur in a state-of-the-art screening program?
    Gynecol Oncol. 2017 Jun 10. pii: S0090-8258(17)30898.
    PubMed     Text format     Abstract available


  209. FREY MK, Ellis AE, Koontz LM, Shyne S, et al
    Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum.
    Gynecol Oncol. 2017 Jun 8. pii: S0090-8258(17)30885.
    PubMed     Text format     Abstract available



  210. A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer.
    Gynecol Oncol. 2017 Jun 7. pii: S0090-8258(17)30895.
    PubMed     Text format     Abstract available


  211. VOGEL TJ, Goodman MT, Li AJ, Jeon CY, et al
    Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Jun 5. pii: S0090-8258(17)30848.
    PubMed     Text format     Abstract available


  212. RANDALL LM, Pothuri B, Swisher EM, Diaz JP, et al
    Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper.
    Gynecol Oncol. 2017 Jun 5. pii: S0090-8258(17)30897.
    PubMed     Text format     Abstract available


  213. SEAGLE BL, Shilpi A, Buchanan S, Goodman C, et al
    Low-grade and high-grade endometrial stromal sarcoma: A National Cancer Database study.
    Gynecol Oncol. 2017 Jun 5. pii: S0090-8258(17)30892.
    PubMed     Text format     Abstract available


  214. CHUNG TKH, Cheung TH, Yim SF, Yu MY, et al
    Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women.
    Gynecol Oncol. 2017 Jun 3. pii: S0090-8258(17)30894.
    PubMed     Text format     Abstract available


  215. MATSUMOTO Y, Mabuchi S, Kozasa K, Kuroda H, et al
    The significance of tumor-associated neutrophil density in uterine cervical cancer treated with definitive radiotherapy.
    Gynecol Oncol. 2017;145:469-475.
    PubMed     Text format     Abstract available


  216. NELSON BH, Jazaeri AA
    Immunotherapy for gynecological cancers: opportunities abound.
    Gynecol Oncol. 2017;145:411-412.
    PubMed     Text format    


  217. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Complete resection of locally advanced ovarian carcinoma fixed to the pelvic sidewall and involving external and internal iliac vessels.
    Gynecol Oncol. 2017 Jun 1. pii: S0090-8258(17)30887.
    PubMed     Text format     Abstract available


  218. SINNO AK, Li X, Thompson RE, Tanner EJ 3rd, et al
    Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care.
    Gynecol Oncol. 2017;145:493-499.
    PubMed     Text format     Abstract available


  219. MELTZER-GUNNES CJ, Smastuen MC, Kristensen GB, Trope CG, et al
    Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival.
    Gynecol Oncol. 2017;145:543-548.
    PubMed     Text format     Abstract available


  220. BRACHOVA P, Alvarez NS, Van Voorhis BJ, Christenson LK, et al
    Cytidine deaminase Apobec3a induction in fallopian epithelium after exposure to follicular fluid.
    Gynecol Oncol. 2017;145:577-583.
    PubMed     Text format     Abstract available


    May 2017
  221. PLANTE M, Stanleigh J, Renaud MC, Sebastianelli A, et al
    Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter?
    Gynecol Oncol. 2017 May 31. pii: S0090-8258(17)30880.
    PubMed     Text format     Abstract available


  222. DILLEY SE, Havrilesky LJ, Bakkum-Gamez J, Cohn DE, et al
    Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention.
    Gynecol Oncol. 2017 May 31. pii: S0090-8258(17)30890.
    PubMed     Text format     Abstract available


  223. KANAO H, Aoki Y, Hisa T, Takeshima N, et al
    Total laparoscopic pelvic exenteration for a laterally recurrent cervical carcinoma with a vesicovaginal fistula that developed after concurrent chemoradiotherapy.
    Gynecol Oncol. 2017 May 30. pii: S0090-8258(17)30886.
    PubMed     Text format     Abstract available


  224. HOLLOWAY RW, Abu-Rustum NR, Backes FJ, Boggess JF, et al
    Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations.
    Gynecol Oncol. 2017 May 28. pii: S0090-8258(17)30883.
    PubMed     Text format     Abstract available


  225. EGGINK FA, Mom CH, Boll D, Ezendam NPM, et al
    Compliance with adjuvant treatment guidelines in endometrial cancer: room for improvement in high risk patients.
    Gynecol Oncol. 2017 May 25. pii: S0090-8258(17)30881.
    PubMed     Text format     Abstract available


  226. STEEN R, Dahl AA, Hess SL, Kiserud CE, et al
    A study of chronic fatigue in Norwegian cervical cancer survivors.
    Gynecol Oncol. 2017 May 25. pii: S0090-8258(17)30884.
    PubMed     Text format     Abstract available


  227. FABER MT, Frederiksen K, Jensen A, Aarslev PB, et al
    Time trends in the incidence of hysterectomy-corrected overall, type 1 and type 2 endometrial cancer in Denmark 1978-2014.
    Gynecol Oncol. 2017 May 23. pii: S0090-8258(17)30854.
    PubMed     Text format     Abstract available


  228. JAMIESON A, Sykes P, Eva L, Bergzoll C, et al
    Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
    Gynecol Oncol. 2017 May 23. pii: S0090-8258(17)30879.
    PubMed     Text format     Abstract available


  229. MALAGON-BLACKWELL EM, Seagle BL, Nieves-Neira W, Shahabi S, et al
    The Hispanic Paradox in endometrial cancer: A National Cancer Database study.
    Gynecol Oncol. 2017 May 23. pii: S0090-8258(17)30882.
    PubMed     Text format     Abstract available


  230. KALOGERA E, Roy D, Khurana A, Mondal S, et al
    Quinacrine in endometrial cancer: Repurposing an old antimalarial drug.
    Gynecol Oncol. 2017 May 22. pii: S0090-8258(17)30803.
    PubMed     Text format     Abstract available


  231. MERT I, Chhina J, Allo G, Dai J, et al
    Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
    Gynecol Oncol. 2017 May 22. pii: S0090-8258(17)30871.
    PubMed     Text format     Abstract available


  232. HOPKINS L, Brown-Broderick J, Hearn J, Malcolm J, et al
    Implementation of a referral to discharge glycemic control initiative for reduction of surgical site infections in gynecologic oncology patients.
    Gynecol Oncol. 2017 May 20. pii: S0090-8258(17)30874.
    PubMed     Text format     Abstract available


  233. SEAGLE BL, Ann P, Butler S, Shahabi S, et al
    Ovarian granulosa cell tumor: A National Cancer Database study.
    Gynecol Oncol. 2017 May 19. pii: S0090-8258(17)30873.
    PubMed     Text format     Abstract available


  234. REYES HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, et al
    High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
    Gynecol Oncol. 2017 May 19. pii: S0090-8258(17)30870.
    PubMed     Text format     Abstract available


  235. SOLIMAN PT, Westin SN, Dioun S, Sun CC, et al
    A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer.
    Gynecol Oncol. 2017 May 18. pii: S0090-8258(17)30855.
    PubMed     Text format     Abstract available


  236. DINKIC C, Eichbaum M, Schmidt M, Grischke EM, et al
    Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
    Gynecol Oncol. 2017 May 18. pii: S0090-8258(17)30852.
    PubMed     Text format     Abstract available


  237. CYBULSKA P, Goss C, Tew WP, Parameswaran R, et al
    Indications for and complications of transfusion and the management of gynecologic malignancies.
    Gynecol Oncol. 2017 May 18. pii: S0090-8258(17)30849.
    PubMed     Text format     Abstract available


  238. ERIKSSON AGZ, Graul A, Yu MC, Halko A, et al
    Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
    Gynecol Oncol. 2017 May 17. pii: S0090-8258(17)30875.
    PubMed     Text format     Abstract available


  239. LUTGENDORF SK, Shinn E, Carter J, Leighton S, et al
    Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.
    Gynecol Oncol. 2017 May 17. pii: S0090-8258(17)30846.
    PubMed     Text format     Abstract available


  240. WOLF B, Ganzer R, Stolzenburg JU, Hentschel B, et al
    Extended mesometrial resection (EMMR): Surgical approach to the treatment of locally advanced cervical cancer based on the theory of ontogenetic cancer fields.
    Gynecol Oncol. 2017 May 16. pii: S0090-8258(17)30845.
    PubMed     Text format     Abstract available


  241. PARK JY, Seong SJ, Kim TJ, Kim JW, et al
    Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer.
    Gynecol Oncol. 2017 May 16. pii: S0090-8258(17)30807.
    PubMed     Text format     Abstract available


  242. BARBER EL, Doll KM, Gehrig PA
    Hospital readmission after ovarian cancer surgery: Are we measuring surgical quality?
    Gynecol Oncol. 2017 May 15. pii: S0090-8258(17)30851.
    PubMed     Text format     Abstract available


  243. EDMONDSON RJ, Crosbie EJ, Nickkho-Amiry M, Kaufmann A, et al
    Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
    Gynecol Oncol. 2017 May 13. pii: S0090-8258(17)30853.
    PubMed     Text format     Abstract available


  244. COHEN JG, Prendergast E, Geddings JE, Walts AE, et al
    Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer.
    Gynecol Oncol. 2017 May 10. pii: S0090-8258(17)30802.
    PubMed     Text format     Abstract available


  245. GARCIA C, Yao A, Camacho F, Balkrishnan R, et al
    A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.
    Gynecol Oncol. 2017 May 9. pii: S0090-8258(17)30847.
    PubMed     Text format     Abstract available


  246. TANENBAUM LM, Mantzavinou A, Subramanyam KS, Del Carmen MG, et al
    Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter.
    Gynecol Oncol. 2017 May 9. pii: S0090-8258(17)30795.
    PubMed     Text format     Abstract available


  247. ENG KH, Morrell K, Starbuck K, Spring-Robinson C, et al
    Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer.
    Gynecol Oncol. 2017 May 8. pii: S0090-8258(17)30844.
    PubMed     Text format     Abstract available


  248. DE DONATO M, Petrillo M, Martinelli E, Filippetti F, et al
    Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.
    Gynecol Oncol. 2017 May 8. pii: S0090-8258(17)30806.
    PubMed     Text format     Abstract available


  249. GRABOSCH S, Tseng G, Edwards RP, Lankes HA, et al
    Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
    Gynecol Oncol. 2017 May 5. pii: S0090-8258(17)30787.
    PubMed     Text format     Abstract available


  250. BEAMAN KD, Dambaeva S, Katara GK, Kulshrestha A, et al
    The immune response in pregnancy and in cancer is active and supportive of placental and tumor cell growth not their destruction.
    Gynecol Oncol. 2017 May 3. pii: S0090-8258(17)30800.
    PubMed     Text format     Abstract available


  251. ESSEL KG, Bruegl A, Gershenson DM, Ramondetta LM, et al
    Salvage chemotherapy for gestational trophoblastic neoplasia: Utility or futility?
    Gynecol Oncol. 2017 May 2. pii: S0090-8258(17)30798.
    PubMed     Text format     Abstract available


  252. MENDERES G, Bonazzoli E, Bellone S, Black J, et al
    SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
    Gynecol Oncol. 2017 May 1. pii: S0090-8258(17)30804.
    PubMed     Text format     Abstract available


  253. KAMRAN SC, Manuel MM, Cho LP, Damato AL, et al
    Comparison of outcomes for MR-guided versus CT-guided high-dose-rate interstitial brachytherapy in women with locally advanced carcinoma of the cervix.
    Gynecol Oncol. 2017;145:284-290.
    PubMed     Text format     Abstract available


  254. ANVEDEN A, Taube M, Peltonen M, Jacobson P, et al
    Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study.
    Gynecol Oncol. 2017;145:224-229.
    PubMed     Text format     Abstract available


  255. BRINTON LA, Thistle JE, Liao LM, Trabert B, et al
    Epidemiology of vulvar neoplasia in the NIH-AARP Study.
    Gynecol Oncol. 2017;145:298-304.
    PubMed     Text format     Abstract available


  256. ALTMAN AD, Robinson C
    Vulvar postoperative care, gestalt or evidence based medicine? A comprehensive systematic review.
    Gynecol Oncol. 2017;145:386-392.
    PubMed     Text format     Abstract available


  257. DATTA NR, Stutz E, Liu M, Rogers S, et al
    Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2017;145:374-385.
    PubMed     Text format     Abstract available


  258. ARGENTA PA
    Attacking obesity-related diseases at the source - Is bariatric surgery the next wave in cancer prevention?
    Gynecol Oncol. 2017;145:219-220.
    PubMed     Text format    


    April 2017
  259. HOLMAN LL, Pal N, Iglesias DA, Soliman PT, et al
    Factors prognostic of survival in advanced-stage uterine serous carcinoma.
    Gynecol Oncol. 2017 Apr 29. pii: S0090-8258(17)30799.
    PubMed     Text format     Abstract available


  260. KONG Y, Yang J, Jiang F, Zhao J, et al
    Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: A retrospective cohort study.
    Gynecol Oncol. 2017 Apr 28. pii: S0090-8258(17)30791.
    PubMed     Text format     Abstract available


  261. COLON-OTERO G, Weroha SJ, Foster NR, Haluska P, et al
    Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
    Gynecol Oncol. 2017 Apr 28. pii: S0090-8258(17)30801.
    PubMed     Text format     Abstract available


  262. LEE J, Lin JB, Chang CL, Jan YT, et al
    Prophylactic lower para-aortic irradiation using intensity-modulated radiotherapy mitigates the risk of para-aortic recurrence in locally advanced cervical cancer: A 10-year institutional experience.
    Gynecol Oncol. 2017 Apr 27. pii: S0090-8258(17)30797.
    PubMed     Text format     Abstract available


  263. VENERIS JT, Darcy KM, Mhawech-Fauceglia P, Tian C, et al
    High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
    Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30793.
    PubMed     Text format     Abstract available


  264. CANTRELL LA, Backes F
    Highlights from the Society of Gynecologic Oncology 2017 Annual Meeting on Women's Cancer.
    Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30772.
    PubMed     Text format    


  265. BOOKMAN MA, Tyczynski JE, Espirito JL, Wilson TW, et al
    Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30792.
    PubMed     Text format     Abstract available


  266. PETERS ML, Garber JE, Tung N
    Managing hereditary breast cancer risk in women with and without ovarian cancer.
    Gynecol Oncol. 2017 Apr 25. pii: S0090-8258(17)30794.
    PubMed     Text format     Abstract available


  267. HARPER DM, DeMars LR
    HPV vaccines - A review of the first decade.
    Gynecol Oncol. 2017 Apr 22. pii: S0090-8258(17)30774.
    PubMed     Text format     Abstract available


  268. BAKER WD, Pierce SR, Mills AM, Gehrig PA, et al
    Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women.
    Gynecol Oncol. 2017 Apr 18. pii: S0090-8258(17)30776.
    PubMed     Text format     Abstract available


  269. KATCHMAN BA, Chowell D, Wallstrom G, Vitonis AF, et al
    Autoantibody biomarkers for the detection of serous ovarian cancer.
    Gynecol Oncol. 2017 Apr 17. pii: S0090-8258(17)30775.
    PubMed     Text format     Abstract available


  270. PHILLIPS A, Balega J, Nevin J, Singh K, et al
    Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer.
    Gynecol Oncol. 2017 Apr 12. pii: S0090-8258(17)30786.
    PubMed     Text format     Abstract available


  271. EMI BRETSCHNEIDER C, Bensen JT, Geller EJ, Gehrig PA, et al
    Perioperative sexual interest in women with suspected gynecologic malignancies.
    Gynecol Oncol. 2017 Apr 12. pii: S0090-8258(17)30771.
    PubMed     Text format     Abstract available


  272. DEL CARMEN MG, Annunziata CM, Rice LW
    The clinical trials crisis in gynecologic oncology.
    Gynecol Oncol. 2017 Apr 11. pii: S0090-8258(17)30773.
    PubMed     Text format    


  273. SHINN EH, Valentine A, Baum G, Carmack C, et al
    Comparison of four brief depression screening instruments in ovarian cancer patients: Diagnostic accuracy using traditional versus alternative cutpoints.
    Gynecol Oncol. 2017 Apr 8. pii: S0090-8258(17)30240.
    PubMed     Text format     Abstract available


  274. SIDDIQUI MK, Tyczynski J, Pahwa A, Fernandes AW, et al
    Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer.
    Gynecol Oncol. 2017 Apr 7. pii: S0090-8258(17)30770.
    PubMed     Text format     Abstract available


  275. GRAYBILL WS, Pothuri B, Chase DM, Monk BJ, et al
    Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30724.
    PubMed     Text format    


  276. BAIOCCHI G, de Brot L, Faloppa CC, Mantoan H, et al
    Is parametrectomy always necessary in early-stage cervical cancer?
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30769.
    PubMed     Text format     Abstract available


  277. SZENDER JB, Papanicolau-Sengos A, Eng KH, Miliotto AJ, et al
    NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30726.
    PubMed     Text format     Abstract available


  278. GARCIA-SOTO AE, Schreiber T, Strbo N, Ganjei-Azar P, et al
    Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30765.
    PubMed     Text format    


  279. NITSCHMANN CC, Multinu F, Bakkum-Gamez JN, Langstraat CL, et al
    Vaginal vs. robotic hysterectomy for patients with endometrial cancer: A comparison of outcomes and cost of care.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30203.
    PubMed     Text format     Abstract available


  280. CREASMAN WT, Ali S, Mutch DG, Zaino RJ, et al
    Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30233.
    PubMed     Text format     Abstract available


  281. EYSBOUTS YK, Massuger LF, IntHout J, Lok CA, et al
    The added value of hysterectomy in the management of gestational trophoblastic neoplasia.
    Gynecol Oncol. 2017 Apr 5. pii: S0090-8258(17)30234.
    PubMed     Text format     Abstract available


  282. HAVRILESKY LJ, Moss HA, Chino J, Myers ER, et al
    Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.
    Gynecol Oncol. 2017 Apr 5. pii: S0090-8258(17)30241.
    PubMed     Text format     Abstract available


  283. HEMMING ML, Wagner AJ, Nucci MR, Chiang S, et al
    YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy.
    Gynecol Oncol. 2017 Apr 5. pii: S0090-8258(17)30237.
    PubMed     Text format     Abstract available


  284. LI H, Sheng Y, Zhang Y, Gao N, et al
    MicroRNA-138 is a potential biomarker and tumor suppressor in human cervical carcinoma by reversely correlated with TCF3 gene.
    Gynecol Oncol. 2017 Apr 3. pii: S0090-8258(17)30062.
    PubMed     Text format     Abstract available


  285. SONG T, Kim MK, Jung YW, Yun BS, et al
    Minimally invasive compared with open surgery in patients with borderline ovarian tumors.
    Gynecol Oncol. 2017 Apr 2. pii: S0090-8258(17)30235.
    PubMed     Text format     Abstract available


  286. SEAGLE BL, Kanis M, Kocherginsky M, Strauss JB, et al
    Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
    Gynecol Oncol. 2017;145:71-77.
    PubMed     Text format     Abstract available


  287. SEAGLE BL, Sobecki-Rausch J, Strohl AE, Shilpi A, et al
    Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
    Gynecol Oncol. 2017;145:61-70.
    PubMed     Text format     Abstract available


  288. HERZOG TJ, Cohn DE
    Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right?
    Gynecol Oncol. 2017;145:1-2.
    PubMed     Text format    


  289. RODRIGUEZ-GARCIA A, Minutolo NG, Robinson JM, Powell DJ, et al
    T-cell target antigens across major gynecologic cancers.
    Gynecol Oncol. 2017 Apr 1. pii: S0090-8258(17)30725.
    PubMed     Text format     Abstract available


  290. BOULAY E, Galczynski K, Canis M, Bourdel N, et al
    Laparoscopic pelvic lymphadenectomy in 10 steps - let's make it easier!
    Gynecol Oncol. 2017;145:217-218.
    PubMed     Text format    


    March 2017
  291. WARREN JL, Harlan LC, Trimble EL, Stevens J, et al
    Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
    Gynecol Oncol. 2017 Mar 31. pii: S0090-8258(17)30232.
    PubMed     Text format     Abstract available


  292. SALANI R, Khanna N, Frimer M, Bristow RE, et al
    An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations.
    Gynecol Oncol. 2017 Mar 31. pii: S0090-8258(17)30238.
    PubMed     Text format     Abstract available


  293. PARK JY, Kim DY, Suh DS, Kim JH, et al
    Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors.
    Gynecol Oncol. 2017 Mar 31. pii: S0090-8258(17)30239.
    PubMed     Text format     Abstract available


  294. BARBER EL, Dusetzina SB, Stitzenberg KB, Rossi EC, et al
    Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.
    Gynecol Oncol. 2017 Mar 30. pii: S0090-8258(17)30230.
    PubMed     Text format     Abstract available


  295. LIU CY, Elias KM, Howitt BE, Lee LJ, et al
    Sentinel lymph node mapping reduces practice pattern variations in surgical staging for endometrial adenocarcinoma: A before and after study.
    Gynecol Oncol. 2017 Mar 28. pii: S0090-8258(17)30227.
    PubMed     Text format     Abstract available


  296. SCOTT SA, van der Zanden C, Cai E, McGahan CE, et al
    Prognostic significance of peritoneal cytology in low-intermediate risk endometrial cancer.
    Gynecol Oncol. 2017 Mar 27. pii: S0090-8258(17)30228.
    PubMed     Text format     Abstract available


  297. DRIVER JA, Viswanathan AN
    Frailty measure is more predictive of outcomes after curative therapy for endometrial cancer than traditional risk factors in women 60 and older.
    Gynecol Oncol. 2017 Mar 27. pii: S0090-8258(17)30226.
    PubMed     Text format     Abstract available


  298. BREGAR A, Deshpande A, Grange C, Zi T, et al
    Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Gynecol Oncol. 2017 Mar 24. pii: S0090-8258(17)30207.
    PubMed     Text format     Abstract available


  299. CHAM S, Huang Y, Tergas AI, Hou JY, et al
    Utility of radiation therapy for early-stage uterine papillary serous carcinoma.
    Gynecol Oncol. 2017 Mar 23. pii: S0090-8258(17)30204.
    PubMed     Text format     Abstract available


  300. JANDIAL DA, Brady WE, Howell SB, Lankes HA, et al
    A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Mar 21. pii: S0090-8258(17)30229.
    PubMed     Text format     Abstract available


  301. RUTLEDGE TL, Kano M, Guest D, Sussman A, et al
    Optimizing endometrial cancer follow-up and survivorship care for rural and other underserved women: Patient and provider perspectives.
    Gynecol Oncol. 2017 Mar 18. pii: S0090-8258(17)30225.
    PubMed     Text format     Abstract available


  302. K AU K, Peterson N, Truesdell P, Reid-Schachter G, et al
    CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    Gynecol Oncol. 2017 Mar 16. pii: S0090-8258(17)30208.
    PubMed     Text format     Abstract available


  303. JESKE YW, Ali S, Byron SA, Gao F, et al
    FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Mar 14. pii: S0090-8258(17)30152.
    PubMed     Text format     Abstract available


  304. MCGEE J, Giannakeas V, Karlan B, Lubinski J, et al
    Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    Gynecol Oncol. 2017 Mar 14. pii: S0090-8258(17)30153.
    PubMed     Text format     Abstract available


  305. NASIOUDIS D, Kanninen TT, Holcomb K, Sisti G, et al
    Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors.
    Gynecol Oncol. 2017 Mar 11. pii: S0090-8258(17)30205.
    PubMed     Text format     Abstract available


  306. WYSHAM WZ, Schaffer EM, Coles T, Roque DR, et al
    Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
    Gynecol Oncol. 2017 Mar 10. pii: S0090-8258(17)30160.
    PubMed     Text format     Abstract available


  307. COWAN RA, Eriksson AG, Jaber SM, Zhou Q, et al
    A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2017 Mar 9. pii: S0090-8258(17)30121.
    PubMed     Text format     Abstract available


  308. RADER JS, Sill MW, Beumer JH, Lankes HA, et al
    A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Mar 9. pii: S0090-8258(17)30161.
    PubMed     Text format     Abstract available


  309. DE ROOIJ BH, Ezendam NP, Nicolaije KA, Caroline Vos M, et al
    Effects of Survivorship Care Plans on patient reported outcomes in ovarian cancer during 2-year follow-up - The ROGY care trial.
    Gynecol Oncol. 2017 Mar 7. pii: S0090-8258(17)30162.
    PubMed     Text format     Abstract available


  310. VAN BROEKHOVEN ME, de Rooij BH, Pijnenborg JM, Vos MC, et al
    Illness perceptions and changes in lifestyle following a gynecological cancer diagnosis: A longitudinal analysis.
    Gynecol Oncol. 2017 Mar 6. pii: S0090-8258(17)30157.
    PubMed     Text format     Abstract available


  311. LEE M, Kim EJ, Cho Y, Kim S, et al
    Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Mar 5. pii: S0090-8258(17)30163.
    PubMed     Text format     Abstract available


  312. WANG YM, Wang CJ, Fang FM, Chen HC, et al
    Differences in the outcomes and complications between elderly and younger uterine cervical cancer patients treated by definitive radiotherapy - A propensity score-matched study.
    Gynecol Oncol. 2017 Mar 5. pii: S0090-8258(17)30155.
    PubMed     Text format     Abstract available


  313. COHN DE, Ko E, Meyer LA, Wright JD, et al
    The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations.
    Gynecol Oncol. 2017 Mar 1. pii: S0090-8258(17)30145.
    PubMed     Text format    


  314. VAN DER LINDEN M, Schuurman M, Bulten J, van der Aa M, et al
    Incidence and survival of glandular vulvar malignancies in the Netherlands.
    Gynecol Oncol. 2017;144:553-557.
    PubMed     Text format     Abstract available


  315. O'HANLAN KA, Sten MS, Halliday DM, Sastry RB, et al
    Comprehensive laparoscopic lymphadenectomy from the deep circumflex iliac vein to the renal veins: Impact on quality of life.
    Gynecol Oncol. 2017;144:592-597.
    PubMed     Text format     Abstract available


  316. SEROR J, Roulot A, Guillot E, Rouzier R, et al
    Colpoplasty by laparoscopic modified Davydov's procedure.
    Gynecol Oncol. 2017;144:647-648.
    PubMed     Text format     Abstract available


    February 2017
  317. ALVAREZ RD, Fowler WC Jr
    The times they are a-changin' - Transformation of accreditation and certification in gynecologic oncology.
    Gynecol Oncol. 2017 Feb 27. pii: S0090-8258(17)30156.
    PubMed     Text format    


  318. FOX E, McCuaig J, Demsky R, Shuman C, et al
    Corrigendum to "The sooner the better: Genetic testing following ovarian cancer diagnosis" [Gynecol. Oncol. 137 (2015) 423-429].
    Gynecol Oncol. 2017 Feb 27. pii: S0090-8258(17)30142.
    PubMed     Text format    


  319. CHASE DM, Chaplin DJ, Monk BJ
    The development and use of vascular targeted therapy in ovarian cancer.
    Gynecol Oncol. 2017 Feb 23. pii: S0090-8258(17)30075.
    PubMed     Text format     Abstract available


  320. SAED GM, Diamond MP, Fletcher NM
    Updates of the role of oxidative stress in the pathogenesis of ovarian cancer.
    Gynecol Oncol. 2017 Feb 23. pii: S0090-8258(17)30154.
    PubMed     Text format     Abstract available


  321. KOMIYAMA S, Manrai M, Takahashi R, Takeya C, et al
    Safe dissection of high paraaortic lymph nodes superior to the renal vein in ovarian, primary peritoneal, or fallopian tube cancer by the "Komiyama's maneuver", a modification of Kocher's maneuver.
    Gynecol Oncol. 2017 Feb 22. pii: S0090-8258(17)30126.
    PubMed     Text format     Abstract available


  322. FELICES M, Chu S, Kodal B, Bendzick L, et al
    IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
    Gynecol Oncol. 2017 Feb 21. pii: S0090-8258(17)30149.
    PubMed     Text format     Abstract available


  323. BUTTARELLI M, Mascilini F, Zannoni GF, Ciucci A, et al
    Hormone receptor expression profile of low-grade serous ovarian cancers.
    Gynecol Oncol. 2017 Feb 20. pii: S0090-8258(17)30150.
    PubMed     Text format     Abstract available


  324. RING KL, Yemelyanova AV, Soliman PT, Frumovitz MM, et al
    Potential immunotherapy targets in recurrent cervical cancer.
    Gynecol Oncol. 2017 Feb 20. pii: S0090-8258(17)30148.
    PubMed     Text format     Abstract available


  325. SIOULAS VD, Schiavone MB, Kadouri D, Zivanovic O, et al
    Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Gynecol Oncol. 2017 Feb 18. pii: S0090-8258(17)30144.
    PubMed     Text format     Abstract available


  326. ETHIER JL, Desautels DN, Templeton AJ, Oza A, et al
    Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis.
    Gynecol Oncol. 2017 Feb 17. pii: S0090-8258(17)30147.
    PubMed     Text format     Abstract available


  327. MATSUO K, Machida H, Takiuchi T, Garcia-Sayre J, et al
    Prognosis of women with apparent stage I endometrial cancer who had supracervical hysterectomy.
    Gynecol Oncol. 2017 Feb 16. pii: S0090-8258(17)30115.
    PubMed     Text format     Abstract available


  328. ROSS J, Braswell KV, da Silva LM, Mujica F, et al
    Unraveling the etiology of ovarian cancer racial disparity in the deep south: Is it nature or nurture?
    Gynecol Oncol. 2017 Feb 16. pii: S0090-8258(17)30146.
    PubMed     Text format     Abstract available


  329. MATSUO K, Omatsu K, Ross MS, Johnson MS, et al
    Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
    Gynecol Oncol. 2017 Feb 16. pii: S0090-8258(17)30080.
    PubMed     Text format     Abstract available


  330. BURGHAUS S, Fasching PA, Haberle L, Rubner M, et al
    Genetic risk factors for ovarian cancer and their role for endometriosis risk.
    Gynecol Oncol. 2017 Feb 14. pii: S0090-8258(17)30143.
    PubMed     Text format     Abstract available


  331. KOHLER RS, Kettelhack H, Knipprath-Meszaros AM, Fedier A, et al
    MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
    Gynecol Oncol. 2017 Feb 14. pii: S0090-8258(17)30128.
    PubMed     Text format     Abstract available


  332. SEAGLE BL, Sobecki-Rausch J, Strohl AE, Shilpi A, et al
    Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
    Gynecol Oncol. 2017 Feb 14. pii: S0090-8258(17)30123.
    PubMed     Text format     Abstract available


  333. SUIDAN RS, Ramirez PT, Sarasohn DM, Teitcher JB, et al
    A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2017 Feb 13. pii: S0090-8258(17)30132.
    PubMed     Text format     Abstract available


  334. RICCI S, Stone RL, Fader AN
    Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
    Gynecol Oncol. 2017 Feb 13. pii: S0090-8258(17)30131.
    PubMed     Text format     Abstract available


  335. SKALLEBERG J, Solheim O, Fossa SD, Smastuen MC, et al
    Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
    Gynecol Oncol. 2017 Feb 12. pii: S0090-8258(17)30117.
    PubMed     Text format     Abstract available


  336. CARVAJAL-HAUSDORF DE, Schalper KA, Bai Y, Black J, et al
    Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
    Gynecol Oncol. 2017 Feb 11. pii: S0090-8258(17)30079.
    PubMed     Text format     Abstract available


  337. SEAGLE BL, Shahabi S
    Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30125.
    PubMed     Text format     Abstract available


  338. LAIRSON DR, Fu S, Chan W, Xu L, et al
    Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30122.
    PubMed     Text format     Abstract available


  339. GEPPERT B, Lonnerfors C, Bollino M, Arechvo A, et al
    A study on uterine lymphatic anatomy for standardization of pelvic sentinel lymph node detection in endometrial cancer.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30130.
    PubMed     Text format     Abstract available


  340. MAI PL, Piedmonte M, Han PK, Moser RP, et al
    Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30119.
    PubMed     Text format     Abstract available


  341. LEFRINGHOUSE JR, Elder JW, Baldwin LA, Miller RW, et al
    Prospective validation of an intraoperative algorithm to guide surgical staging in early endometrial cancer.
    Gynecol Oncol. 2017 Feb 9. pii: S0090-8258(17)30076.
    PubMed     Text format     Abstract available


  342. SALVO G, Ramirez PT, Levenback CF, Munsell MF, et al
    Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer.
    Gynecol Oncol. 2017 Feb 7. pii: S0090-8258(17)30116.
    PubMed     Text format     Abstract available


  343. OBERMAIR A, Simunovic M, Isenring L, Janda M, et al
    Nutrition interventions in patients with gynecological cancers requiring surgery.
    Gynecol Oncol. 2017 Feb 4. pii: S0090-8258(17)30072.
    PubMed     Text format     Abstract available


  344. KENTWELL M, Dow E, Antill Y, Wrede CD, et al
    Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
    Gynecol Oncol. 2017 Feb 3. pii: S0090-8258(17)30074.
    PubMed     Text format     Abstract available


  345. SMITH JA, Mathew L, Burney M, Nyshadham P, et al
    Corrigendum to 'Equivalency challenge: evaluation of Lipodox(R) as the generic equivalent for Doxil(R) in a human ovarian cancer orthotropic mouse model' [Gynecol. Oncol. 141 (2016) 357-363].
    Gynecol Oncol. 2017;144:448.
    PubMed     Text format    


  346. WESTIN SN, Coleman RL
    Individualized Medicine in Ovarian Cancer: Are We There Yet?
    Gynecol Oncol. 2017;144:229-231.
    PubMed     Text format    


  347. COHN DE, Backes FJ, Wallbillich JJ, Bixel K, et al
    Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30067.
    PubMed     Text format     Abstract available


  348. BREGAR AJ, Alejandro Rauh-Hain J, Spencer R, Clemmer JT, et al
    Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30068.
    PubMed     Text format     Abstract available


  349. EOH KJ, Park JS, Park HS, Lee ST, et al
    BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30070.
    PubMed     Text format     Abstract available


  350. O'DONNELL RL, Verleye L, Ratnavelu N, Galaal K, et al
    Locally advanced vulva cancer: A single centre review of anovulvectomy and a systematic review of surgical, chemotherapy and radiotherapy alternatives. Is an international collaborative RCT destined for the "too difficult to do" box?
    Gynecol Oncol. 2017;144:438-447.
    PubMed     Text format     Abstract available


  351. DANIELE G, Lorusso D, Scambia G, Cecere SC, et al
    Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
    Gynecol Oncol. 2017;144:256-259.
    PubMed     Text format     Abstract available


  352. VERLOOP J, van Leeuwen FE, Helmerhorst TJ, de Kok IM, et al
    Risk of cervical intra-epithelial neoplasia and invasive cancer of the cervix in DES daughters.
    Gynecol Oncol. 2017;144:305-311.
    PubMed     Text format     Abstract available


  353. GIEN LT, Sutradhar R, Thomas G, Covens A, et al
    Does a groin node dissection in vulvar cancer affect groin recurrence and overall survival?: Results from a population-based cohort study.
    Gynecol Oncol. 2017;144:318-323.
    PubMed     Text format     Abstract available


    January 2017
  354. WALLACE S, Kumar A, Mc Gree M, Weaver A, et al
    Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.
    Gynecol Oncol. 2017 Jan 31. pii: S0090-8258(17)30073.
    PubMed     Text format     Abstract available


  355. CHANAKIRA A, Westmark PR, Ong IM, Sheehan JP, et al
    Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.
    Gynecol Oncol. 2017 Jan 29. pii: S0090-8258(17)30066.
    PubMed     Text format     Abstract available


  356. DALTON HJ, Fleming ND, Sun CC, Bhosale P, et al
    Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
    Gynecol Oncol. 2017 Jan 27. pii: S0090-8258(17)30071.
    PubMed     Text format     Abstract available


  357. LIN LH, Maesta I, Braga A, Sun SY, et al
    Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review.
    Gynecol Oncol. 2017 Jan 26. pii: S0090-8258(17)30065.
    PubMed     Text format     Abstract available


  358. MATSUO K, Machida H, Takiuchi T, Grubbs BH, et al
    Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors.
    Gynecol Oncol. 2017 Jan 26. pii: S0090-8258(17)30063.
    PubMed     Text format     Abstract available


  359. SUIDAN RS, He W, Sun CC, Zhao H, et al
    Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia.
    Gynecol Oncol. 2017 Jan 25. pii: S0090-8258(17)30069.
    PubMed     Text format     Abstract available


  360. HO CK, Kornaga EN, Klimowicz AC, Enwere EK, et al
    Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
    Gynecol Oncol. 2017 Jan 25. pii: S0090-8258(16)31689.
    PubMed     Text format     Abstract available


  361. COX BAUER CM, Greer DM, Kram JJ, Kamelle SA, et al
    Corrigendum to 'Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer' [Gynecol. Oncol. 141 (2016) 199-205].
    Gynecol Oncol. 2017 Jan 25. pii: S0090-8258(16)31618.
    PubMed     Text format    


  362. ALETTI GD, Garbi A, Messori P, Achilarre MT, et al
    Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit.
    Gynecol Oncol. 2017 Jan 20. pii: S0090-8258(17)30061.
    PubMed     Text format     Abstract available


  363. WINTERHOFF BJ, Maile M, Mitra AK, Sebe A, et al
    Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.
    Gynecol Oncol. 2017 Jan 19. pii: S0090-8258(17)30059.
    PubMed     Text format     Abstract available


  364. REISS KA, Herman JM, Armstrong D, Zahurak M, et al
    A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian
    Gynecol Oncol. 2017 Jan 18. pii: S0090-8258(17)30060.
    PubMed     Text format     Abstract available


  365. MACHIDA H, Nathenson MJ, Takiuchi T, Adams CL, et al
    Significance of lymph node metastasis on survival of women with uterine adenosarcoma.
    Gynecol Oncol. 2017 Jan 18. pii: S0090-8258(17)30050.
    PubMed     Text format     Abstract available


  366. LEE YJ, Kim DY, Lee SW, Park JY, et al
    A postoperative scoring system for distant recurrence in node-positive cervical cancer patients after radical hysterectomy and pelvic lymph node dissection with para-aortic lymph node sampling or dissection.
    Gynecol Oncol. 2017 Jan 17. pii: S0090-8258(17)30001.
    PubMed     Text format     Abstract available


  367. RASMUSSEN EL, Hannibal CG, Dehlendorff C, Baandrup L, et al
    Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
    Gynecol Oncol. 2017 Jan 17. pii: S0090-8258(17)30039.
    PubMed     Text format     Abstract available


  368. HOW J, Gauthier C, Abitbol J, Lau S, et al
    Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer.
    Gynecol Oncol. 2017 Jan 16. pii: S0090-8258(17)30057.
    PubMed     Text format     Abstract available


  369. HALTIA UM, Andersson N, Yadav B, Farkkila A, et al
    Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.
    Gynecol Oncol. 2017 Jan 16. pii: S0090-8258(16)31681.
    PubMed     Text format     Abstract available


  370. ALEXANDRE E, Sebastien G, Renaud M, Enrica B, et al
    Outcome of early stage cervical cancer patients treated according to a radiosurgical approach: Clinical results and prognostic factors.
    Gynecol Oncol. 2017 Jan 14. pii: S0090-8258(16)31690.
    PubMed     Text format     Abstract available


  371. SWAILES AL, Gockley A, Phaeton R, Kesterson JP, et al
    The Wertheim hysterectomy: Development, modifications, and impact in the present day.
    Gynecol Oncol. 2017 Jan 13. pii: S0090-8258(17)30049.
    PubMed     Text format     Abstract available


  372. LIAO JB, Swensen RE, Ovenell KJ, Hitchcock-Bernhardt KM, et al
    Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer.
    Gynecol Oncol. 2017 Jan 12. pii: S0090-8258(17)30046.
    PubMed     Text format     Abstract available


  373. VON GRUENIGEN VE, Huang HQ, Beumer JH, Lankes HA, et al
    Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Jan 12. pii: S0090-8258(16)31602.
    PubMed     Text format     Abstract available


  374. SEAGLE BL, Kanis M, Kocherginsky M, Strauss JB, et al
    Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
    Gynecol Oncol. 2017 Jan 12. pii: S0090-8258(17)30048.
    PubMed     Text format     Abstract available


  375. GILLEN J, Gunderson C, Greenwade M, Rowland M, et al
    Contribution of age to clinical trial enrollment and tolerance with ovarian cancer.
    Gynecol Oncol. 2017 Jan 10. pii: S0090-8258(16)31687.
    PubMed     Text format     Abstract available


  376. BEDELL S, Manders D, Kehoe S, Lea J, et al
    The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment.
    Gynecol Oncol. 2017 Jan 9. pii: S0090-8258(16)31686.
    PubMed     Text format     Abstract available


  377. ISLAM MM, Banerjee T, Packard CZ, Kotian S, et al
    HDAC10 as a potential therapeutic target in ovarian cancer.
    Gynecol Oncol. 2017 Jan 7. pii: S0090-8258(17)30047.
    PubMed     Text format     Abstract available


  378. TOZZI R, Hardern K, Gubbala K, Garruto Campanile R, et al
    En-bloc resection of the pelvis (EnBRP) in patients with stage IIIC-IV ovarian cancer: A 10 steps standardised technique. Surgical and survival outcomes of primary vs. interval surgery.
    Gynecol Oncol. 2017 Jan 7. pii: S0090-8258(16)31683.
    PubMed     Text format     Abstract available


  379. TUOMI T, Pasanen A, Leminen A, Butzow R, et al
    Prediction of lymphatic dissemination in endometrioid endometrial cancer: Comparison of three risk-stratification models in a single-institution cohort.
    Gynecol Oncol. 2017 Jan 6. pii: S0090-8258(17)30041.
    PubMed     Text format     Abstract available


  380. GOTTLIEB CE, Mills AM, Cross JV, Ring KL, et al
    Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.
    Gynecol Oncol. 2017 Jan 5. pii: S0090-8258(16)31685.
    PubMed     Text format     Abstract available


  381. RYAN NA, Evans DG, Green K, Crosbie EJ, et al
    Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.
    Gynecol Oncol. 2017 Jan 5. pii: S0090-8258(17)30042.
    PubMed     Text format     Abstract available


  382. DIZON DS
    Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection.
    Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31684.
    PubMed     Text format    


  383. PIERCE SR, Stine JE, Gehrig PA, Havrilesky LJ, et al
    Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma.
    Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31688.
    PubMed     Text format     Abstract available


  384. SPREAFICO A, Oza AM, Clarke BA, Mackay HJ, et al
    Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31620.
    PubMed     Text format     Abstract available


  385. ANGIOLO G, Silvestro C, Giovanni A
    Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists.
    Gynecol Oncol. 2017 Jan 2. pii: S0090-8258(16)31621.
    PubMed     Text format     Abstract available


  386. FRUMOVITZ M
    Sentinel Lymph Node Biopsy for Cervical Cancer Patients - What's It Gonna Take?
    Gynecol Oncol. 2017;144:3-4.
    PubMed     Text format    


  387. KARLAN BY
    Gynecologic Oncology 2017 Update: New Features and Expanded Scope.
    Gynecol Oncol. 2017;144:1-2.
    PubMed     Text format    


  388. HYMAN DM, Sill MW, Lankes HA, Piekarz R, et al
    A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
    Gynecol Oncol. 2017;144:96-100.
    PubMed     Text format     Abstract available


  389. BERGAMINI A, Pisano C, Di Napoli M, Arenare L, et al
    Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
    Gynecol Oncol. 2017;144:72-76.
    PubMed     Text format     Abstract available


  390. KIM M, Suh DH, Yang EJ, Lim MC, et al
    Identifying risk factors for occult lower extremity lymphedema using computed tomography in patients undergoing lymphadenectomy for gynecologic cancers.
    Gynecol Oncol. 2017;144:153-158.
    PubMed     Text format     Abstract available


  391. WRIGHT TC JR, Behrens CM, Ranger-Moore J, Rehm S, et al
    Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
    Gynecol Oncol. 2017;144:51-56.
    PubMed     Text format     Abstract available


  392. ABITBOL J, Cohn R, Hunter S, Rombaldi M, et al
    Minimizing pain medication use and its associated costs following robotic surgery.
    Gynecol Oncol. 2017;144:187-192.
    PubMed     Text format     Abstract available


  393. DORNEY KM, Growdon WB, Clemmer J, Rauh-Hain JA, et al
    Patient, treatment and discharge factors associated with hospital readmission within 30days after surgery for vulvar cancer.
    Gynecol Oncol. 2017;144:136-139.
    PubMed     Text format     Abstract available


  394. FRUMOVITZ M, Munsell MF, Burzawa JK, Byers LA, et al
    Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
    Gynecol Oncol. 2017;144:46-50.
    PubMed     Text format     Abstract available


  395. KIM HS, Lee M
    Video endoscopic inguinal lymphadenectomy (VEIL) for vulvar cancer.
    Gynecol Oncol. 2017;144:225-226.
    PubMed     Text format    


    December 2016
  396. KESSOUS R, Laskov I, Abitbol J, Bitharas J, et al
    Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2016 Dec 29. pii: S0090-8258(16)31679.
    PubMed     Text format     Abstract available


  397. PIULATS JM, Guerra E, Gil-Martin M, Roman-Canal B, et al
    Molecular approaches for classifying endometrial carcinoma.
    Gynecol Oncol. 2016 Dec 28. pii: S0090-8258(16)31680.
    PubMed     Text format     Abstract available


  398. BENOIT MF, Ma JF, Upperman BA
    Comparison of 2015 Medicare relative value units for gender-specific procedures: Gynecologic and gynecologic-oncologic versus urologic CPT coding. Has time healed gender-worth?
    Gynecol Oncol. 2016 Dec 23. pii: S0090-8258(16)31624.
    PubMed     Text format     Abstract available


  399. NAROD S, Sopik V
    Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?
    Gynecol Oncol. 2016 Dec 22. pii: S0090-8258(16)31615.
    PubMed     Text format    


  400. MATSUO K, Machida H, Ragab OM, Takiuchi T, et al
    Extent of pelvic lymphadenectomy and use of adjuvant vaginal brachytherapy for early-stage endometrial cancer.
    Gynecol Oncol. 2016 Dec 22. pii: S0090-8258(16)31670.
    PubMed     Text format     Abstract available


  401. CHAN JL, Wang ET
    Oncofertility for women with gynecologic malignancies.
    Gynecol Oncol. 2016 Dec 21. pii: S0090-8258(16)31671.
    PubMed     Text format     Abstract available


  402. SUAREZ AA, Felix AS, Cohn DE
    Bokhman Redux: Endometrial cancer "types" in the 21st century.
    Gynecol Oncol. 2016 Dec 16. pii: S0090-8258(16)31668.
    PubMed     Text format     Abstract available


  403. LEFKOWITS C, Duska L
    Opioid Use in Gynecologic Oncology; Balancing Efficacy, Accessibility and Safety: An SGO Clinical Practice Statement.
    Gynecol Oncol. 2016 Dec 14. pii: S0090-8258(16)31571.
    PubMed     Text format    


  404. DOLL KM, Pinheiro LC, Reeve BB
    Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study.
    Gynecol Oncol. 2016 Dec 14. pii: S0090-8258(16)31623.
    PubMed     Text format     Abstract available


  405. RUBERG JL, Helm CW, Felleman BI, Helm JE, et al
    Is attendance at an ovarian cancer screening clinic a worry-reducing event? Findings from pre- to post-screening.
    Gynecol Oncol. 2016 Dec 13. pii: S0090-8258(16)31616.
    PubMed     Text format     Abstract available


  406. PRENDERGAST EN, Holzapfel M, Mueller JJ, Leitao MM Jr, et al
    Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
    Gynecol Oncol. 2016 Dec 12. pii: S0090-8258(16)31622.
    PubMed     Text format     Abstract available


  407. MARU Y, Tanaka N, Ohira M, Itami M, et al
    Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.
    Gynecol Oncol. 2016 Dec 8. pii: S0090-8258(16)31614.
    PubMed     Text format     Abstract available


  408. RZEPECKA IK, Szafron LM, Stys A, Felisiak-Golabek A, et al
    Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
    Gynecol Oncol. 2016 Dec 7. pii: S0090-8258(16)31597.
    PubMed     Text format     Abstract available


  409. MATZ M, Coleman MP, Sant M, Chirlaque MD, et al
    The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2).
    Gynecol Oncol. 2016 Dec 5. pii: S0090-8258(16)31497.
    PubMed     Text format     Abstract available


  410. MUSA F, Pothuri B, Blank SV, Ling HT, et al
    Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
    Gynecol Oncol. 2016 Dec 5. pii: S0090-8258(16)31612.
    PubMed     Text format     Abstract available


  411. MATSUO K, Ross MS, Bush SH, Yunokawa M, et al
    Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma.
    Gynecol Oncol. 2016 Dec 5. pii: S0090-8258(16)31611.
    PubMed     Text format     Abstract available


  412. KALOGERA E, Nitschmann CC, Dowdy SC, Cliby WA, et al
    A prospective algorithm to reduce anastomotic leaks after rectosigmoid resection for gynecologic malignancies.
    Gynecol Oncol. 2016 Dec 2. pii: S0090-8258(16)31601.
    PubMed     Text format     Abstract available


  413. MATZ M, Coleman MP, Carreira H, Salmeron D, et al
    Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2).
    Gynecol Oncol. 2016 Dec 2. pii: S0090-8258(16)31575.
    PubMed     Text format     Abstract available


  414. DOTTINO JA, Lu KH
    Towards value-based universal Lynch syndrome identification in endometrial cancer patients.
    Gynecol Oncol. 2016;143:451-452.
    PubMed     Text format    


  415. GILL SE, McGree ME, Weaver AL, Cliby WA, et al
    Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gynecol Oncol. 2016 Dec 1. pii: S0090-8258(16)31577.
    PubMed     Text format     Abstract available


    November 2016
  416. ADAMBEKOV S, Goughnour SL, Mansuria S, Donnellan N, et al
    Patient and provider factors associated with endometrial Pipelle sampling failure.
    Gynecol Oncol. 2016 Nov 29. pii: S0090-8258(16)31610.
    PubMed     Text format     Abstract available


  417. SEAGLE BL, Butler SK, Strohl AE, Nieves-Neira W, et al
    Chemotherapy delay after primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2016 Nov 28. pii: S0090-8258(16)31578.
    PubMed     Text format     Abstract available


  418. SAPIENZA LG, Gomes MJ, Calsavara VF, Leitao MM Jr, et al
    Does para-aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta-analysis of randomized clinical trials.
    Gynecol Oncol. 2016 Nov 28. pii: S0090-8258(16)31613.
    PubMed     Text format     Abstract available


  419. KUJI S, Watanabe R, Sato Y, Iwata T, et al
    A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases.
    Gynecol Oncol. 2016 Nov 28. pii: S0090-8258(16)31576.
    PubMed     Text format     Abstract available


  420. NASIOUDIS D, Chapman-Davis E, Witkin SS, Holcomb K, et al
    Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma.
    Gynecol Oncol. 2016 Nov 28. pii: S0090-8258(16)31607.
    PubMed     Text format     Abstract available


  421. MILLER RE, Ledermann JA
    The European Society for Medical Oncology 2016 Congress: Highlights and summary of selected abstracts in gynecologic cancers.
    Gynecol Oncol. 2016 Nov 27. pii: S0090-8258(16)31609.
    PubMed     Text format    


  422. ROSS GREEN W, Hathout L, Khan AJ, Elshaikh MA, et al
    Revisiting Milan cervical cancer study: Do the original findings hold in the era of chemotherapy?
    Gynecol Oncol. 2016 Nov 26. pii: S0090-8258(16)31603.
    PubMed     Text format     Abstract available


  423. SULLIVAN SA, Clark LH, Staley AS, Tran AQ, et al
    Association between timing of cervical excision procedure to minimally invasive hysterectomy and surgical complications.
    Gynecol Oncol. 2016 Nov 25. pii: S0090-8258(16)31606.
    PubMed     Text format     Abstract available


  424. BEACHLER DC, Tota JE, Silver MI, Kreimer AR, et al
    Trends in cervical cancer incidence in younger US women from 2000 to 2013.
    Gynecol Oncol. 2016 Nov 25. pii: S0090-8258(16)31600.
    PubMed     Text format     Abstract available


  425. BELLONE S, Bignotti E, Lonardi S, Ferrari F, et al
    Polymerase epsilon (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
    Gynecol Oncol. 2016 Nov 25. pii: S0090-8258(16)31579.
    PubMed     Text format     Abstract available


  426. KONG TW, Lee JD, Son JH, Paek J, et al
    Corrigendum to 'Treatment outcomes in patients with FIGO stage IB-IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: A propensity score matching study' [Gynecol. Oncol. 143 (2016) 77-82].
    Gynecol Oncol. 2016 Nov 24. pii: S0090-8258(16)31522.
    PubMed     Text format    


  427. BARBER EL, Clarke-Pearson DL
    Prevention of venous thromboembolism in gynecologic oncology surgery.
    Gynecol Oncol. 2016 Nov 24. pii: S0090-8258(16)31605.
    PubMed     Text format     Abstract available


  428. KARNEZIS AN, Cho KR
    Of mice and women - Non-ovarian origins of "ovarian" cancer.
    Gynecol Oncol. 2016 Nov 24. pii: S0090-8258(16)31608.
    PubMed     Text format    


  429. DE DECKER K, Speth S, Ter Brugge HG, Bart J, et al
    Staging procedures in patients with mucinous borderline tumors of the ovary do not reveal peritoneal or omental disease.
    Gynecol Oncol. 2016 Nov 23. pii: S0090-8258(16)31604.
    PubMed     Text format     Abstract available


  430. CHENG A, Li M, Kanis MJ, Xu Y, et al
    Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis.
    Gynecol Oncol. 2016 Nov 23. pii: S0090-8258(16)31518.
    PubMed     Text format     Abstract available


  431. MANNE SL, Virtue SM, Ozga M, Kashy D, et al
    A comparison of two psychological interventions for newly-diagnosed gynecological cancer patients.
    Gynecol Oncol. 2016 Nov 22. pii: S0090-8258(16)31581.
    PubMed     Text format     Abstract available


  432. OSBORN V, Schwartz D, Lee YC, Lee A, et al
    Patterns of care of IMRT usage in postoperative management of uterine cancer.
    Gynecol Oncol. 2016 Nov 22. pii: S0090-8258(16)31573.
    PubMed     Text format     Abstract available


  433. SMITH B, McCann GA, Phillips G, Backes FJ, et al
    Less radical surgery for early-stage cervical cancer: Can conization specimens help identify patients at low risk for parametrial involvement?
    Gynecol Oncol. 2016 Nov 21. pii: S0090-8258(16)31598.
    PubMed     Text format     Abstract available


  434. TAYLOR KN, McHale MT, Saenz CC, Plaxe SC, et al
    Diagnosis and treatment of Clostridium difficile (C. diff) colitis: Review of the literature and a perspective in gynecologic oncology.
    Gynecol Oncol. 2016 Nov 19. pii: S0090-8258(16)31580.
    PubMed     Text format     Abstract available


  435. SORIO R, Roemer-Becuwe C, Hilpert F, Gibbs E, et al
    Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
    Gynecol Oncol. 2016 Nov 18. pii: S0090-8258(16)31562.
    PubMed     Text format     Abstract available


  436. HALTIA UM, Hallamaa M, Tapper J, Hynninen J, et al
    Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors.
    Gynecol Oncol. 2016 Nov 18. pii: S0090-8258(16)31574.
    PubMed     Text format     Abstract available


  437. HEITZ F, Hengsbach A, Harter P, Traut A, et al
    Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2016 Nov 16. pii: S0090-8258(16)31567.
    PubMed     Text format     Abstract available


  438. SHIM SH, Kim DY, Lee SJ, Kim SN, et al
    Prediction model for para-aortic lymph node metastasis in patients with locally advanced cervical cancer.
    Gynecol Oncol. 2016 Nov 14. pii: S0090-8258(16)31568.
    PubMed     Text format     Abstract available


  439. DEL CARMEN MG, Rice LW
    International Gynecologic Cancer Society (IGCS) 2016: Meeting report.
    Gynecol Oncol. 2016 Nov 12. pii: S0090-8258(16)31572.
    PubMed     Text format    


  440. CORDEIRO VIDAL G, Babin G, Querleu D, Guyon F, et al
    Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31507.
    PubMed     Text format     Abstract available


  441. LI Y, Zhang HL, Kang S, Zhou RM, et al
    The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31566.
    PubMed     Text format     Abstract available


  442. THOMAS ED, Nugent EK, MacAllister MC, Moxley KM, et al
    Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31564.
    PubMed     Text format     Abstract available


  443. HANNIBAL CG, Vang R, Junge J, Frederiksen K, et al
    A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31563.
    PubMed     Text format     Abstract available


  444. MARCHETTI C, Kristeleit R, McCormack M, Mould T, et al
    Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.
    Gynecol Oncol. 2016 Nov 5. pii: S0090-8258(16)31520.
    PubMed     Text format     Abstract available


  445. WONG AT, Rineer J, Schwartz D, Weiner J, et al
    Patterns of adjuvant radiation usage and survival outcomes for stage I endometrial carcinoma in a large hospital-based cohort.
    Gynecol Oncol. 2016 Nov 4. pii: S0090-8258(16)31521.
    PubMed     Text format     Abstract available


  446. RASPAGLIESI F, Maltese G, Bogani G, Fuca G, et al
    Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study.
    Gynecol Oncol. 2016 Nov 4. pii: S0090-8258(16)31519.
    PubMed     Text format     Abstract available


  447. DAHM-KAHLER P, Borgfeldt C, Holmberg E, Staf C, et al
    Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
    Gynecol Oncol. 2016 Nov 3. pii: S0090-8258(16)31516.
    PubMed     Text format     Abstract available


  448. MILLER CR, Chappell NP, Sledge C, Leath CA 3rd, et al
    Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
    Gynecol Oncol. 2016 Nov 2. pii: S0090-8258(16)31515.
    PubMed     Text format     Abstract available


    October 2016
  449. FALLON J, Park SJ, Yang L, Veruttipong D, et al
    Long term results from a prospective database on high dose rate (HDR) interstitial brachytherapy for primary cervical carcinoma.
    Gynecol Oncol. 2016 Oct 29. pii: S0090-8258(16)31496.
    PubMed     Text format     Abstract available


  450. DESALE MG, Tanner EJ 3rd, Sinno AK, Angarita AA, et al
    Perioperative fluid status and surgical outcomes in patients undergoing cytoreductive surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2016 Oct 28. pii: S0090-8258(16)31501.
    PubMed     Text format     Abstract available


  451. MCCOURT CK, Deng W, Dizon DS, Lankes HA, et al
    A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2016 Oct 28. pii: S0090-8258(16)31502.
    PubMed     Text format     Abstract available


  452. GUPTA V, McGunigal M, Prasad-Hayes M, Kalir T, et al
    Adjuvant radiation therapy is associated with improved overall survival in high-intermediate risk stage I endometrial cancer: A national cancer data base analysis.
    Gynecol Oncol. 2016 Oct 25. pii: S0090-8258(16)31500.
    PubMed     Text format     Abstract available


  453. HOROWITZ NS, Goldstein DP, Berkowitz RS
    Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities.
    Gynecol Oncol. 2016 Oct 24. pii: S0090-8258(16)31505.
    PubMed     Text format     Abstract available


  454. GOVERDE A, Spaander MC, van Doorn HC, Dubbink HJ, et al
    Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age.
    Gynecol Oncol. 2016 Oct 24. pii: S0090-8258(16)31480.
    PubMed     Text format     Abstract available


  455. BENDIFALLAH S, Ouldamer L, Lavoue V, Canlorbe G, et al
    Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN study Group.
    Gynecol Oncol. 2016 Oct 24. pii: S0090-8258(16)31503.
    PubMed     Text format     Abstract available


  456. KIM JY, Byun SJ, Kim YS, Nam JH, et al
    Disease courses in patients with residual tumor following concurrent chemoradiotherapy for locally advanced cervical cancer.
    Gynecol Oncol. 2016 Oct 24. pii: S0090-8258(16)31509.
    PubMed     Text format     Abstract available


  457. HAQUE W, Verma V, Fakhreddine M, Hatch S, et al
    Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: Analysis of the National Cancer Data Base.
    Gynecol Oncol. 2016 Oct 23. pii: S0090-8258(16)31510.
    PubMed     Text format     Abstract available


  458. HAGEN B, Valla M, Aune G, Ravlo M, et al
    Indocyanine green fluorescence imaging of lymph nodes during robotic-assisted laparoscopic operation for endometrial cancer. A prospective validation study using a sentinel lymph node surgical algorithm.
    Gynecol Oncol. 2016 Oct 21. pii: S0090-8258(16)31506.
    PubMed     Text format     Abstract available


  459. CHAN JK, Java JJ, Fuh K, Monk BJ, et al
    The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG oncology/gynecologic oncology group trials.
    Gynecol Oncol. 2016 Oct 19. pii: S0090-8258(16)31421.
    PubMed     Text format     Abstract available


  460. LEE JY, Kim K, Lee YS, Kim HY, et al
    Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy.
    Gynecol Oncol. 2016 Oct 19. pii: S0090-8258(16)31498.
    PubMed     Text format     Abstract available


  461. GUELI ALLETTI S, Petrillo M, Vizzielli G, Bottoni C, et al
    Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study.
    Gynecol Oncol. 2016 Oct 18. pii: S0090-8258(16)31491.
    PubMed     Text format     Abstract available


  462. MAHMOUD O, Hathout L, Shaaban SG, Elshaikh MA, et al
    Can chemotherapy boost the survival benefit of adjuvant radiotherapy in early stage cervical cancer with intermediate risk factors? A population based study.
    Gynecol Oncol. 2016 Oct 18. pii: S0090-8258(16)31499.
    PubMed     Text format     Abstract available


  463. SEAGLE BL, Dayno M, Strohl AE, Graves S, et al
    Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study.
    Gynecol Oncol. 2016 Oct 16. pii: S0090-8258(16)31495.
    PubMed     Text format     Abstract available


  464. WINTER MC, Tidy JA, Hills A, Ireson J, et al
    Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
    Gynecol Oncol. 2016 Oct 15. pii: S0090-8258(16)31435.
    PubMed     Text format     Abstract available


  465. CRAIG ER, Londono AI, Norian LA, Arend RC, et al
    Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.
    Gynecol Oncol. 2016 Oct 14. pii: S0090-8258(16)31477.
    PubMed     Text format     Abstract available


  466. CAPRIGLIONE S, Plotti F, Montera R, Luvero D, et al
    Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial.
    Gynecol Oncol. 2016 Oct 14. pii: S0090-8258(16)31476.
    PubMed     Text format     Abstract available


  467. LEBLANC E, Narducci F, Bresson L, Hudry D, et al
    Fluorescence-assisted sentinel (SND) and pelvic node dissections by single-port transvaginal laparoscopic surgery, for the management of an endometrial carcinoma (EC) in an elderly obese patient.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31482.
    PubMed     Text format     Abstract available


  468. BAI H, Cao D, Yuan F, Sha G, et al
    Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31481.
    PubMed     Text format     Abstract available


  469. SOLIMAN PT, Zhang Q, Broaddus RR, Westin SN, et al
    Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31483.
    PubMed     Text format     Abstract available


  470. BROWN J, Naumann RW, Seckl MJ, Schink J, et al
    15years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31356.
    PubMed     Text format     Abstract available


  471. KIM HS, Bristow RE, Chang SJ
    Total parietal peritonectomy with en bloc pelvic resection for advanced ovarian cancer with peritoneal carcinomatosis.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31488.
    PubMed     Text format     Abstract available


  472. FADER AN, Java J, Tenney M, Ricci S, et al
    Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis.
    Gynecol Oncol. 2016 Oct 12. pii: S0090-8258(16)31490.
    PubMed     Text format     Abstract available


  473. FLEMING ND, Ramirez PT, Soliman PT, Schmeler KM, et al
    Quality of life after radical trachelectomy for early-stage cervical cancer: A 5-year prospective evaluation.
    Gynecol Oncol. 2016 Oct 11. pii: S0090-8258(16)31484.
    PubMed     Text format     Abstract available


  474. LENNOX GK, Covens A
    Can sentinel lymph node biopsy replace pelvic lymphadenectomy for early cervical cancer?
    Gynecol Oncol. 2016 Oct 11. pii: S0090-8258(16)31358.
    PubMed     Text format     Abstract available


  475. BRYK S, Farkkila A, Butzow R, Leminen A, et al
    Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors.
    Gynecol Oncol. 2016 Oct 8. pii: S0090-8258(16)31473.
    PubMed     Text format     Abstract available


  476. GARCIA-SOTO AE, Java JJ, Nieves Neira W, Pearson JM, et al
    Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
    Gynecol Oncol. 2016 Oct 7. pii: S0090-8258(16)31474.
    PubMed     Text format     Abstract available


  477. LIAO Y, Deng Y, Liu J, Ye Z, et al
    MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression.
    Gynecol Oncol. 2016 Oct 7. pii: S0090-8258(16)31410.
    PubMed     Text format     Abstract available


  478. BOOTHE D, Orton A, Odei B, Stoddard G, et al
    Corrigendum to "Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival" [Gynecol. Oncol. 141 (2016) 421-427].
    Gynecol Oncol. 2016 Oct 7. pii: S0090-8258(16)31429.
    PubMed     Text format    


  479. CHO LP, Manuel M, Catalano P, Lee L, et al
    Outcomes with volume-based dose specification in CT-planned high-dose-rate brachytherapy for stage I-II cervical carcinoma: A 10-year institutional experience.
    Gynecol Oncol. 2016 Oct 6. pii: S0090-8258(16)31423.
    PubMed     Text format     Abstract available


  480. BARRINGTON DA, Dilley SE, Landers EE, Thomas ED, et al
    Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?
    Gynecol Oncol. 2016 Oct 6. pii: S0090-8258(16)31475.
    PubMed     Text format     Abstract available


  481. SHAFRIR AL, Rice MS, Gupta M, Terry KL, et al
    The association between reproductive and hormonal factors and ovarian cancer by estrogen-alpha and progesterone receptor status.
    Gynecol Oncol. 2016 Oct 5. pii: S0090-8258(16)31430.
    PubMed     Text format     Abstract available


  482. WRIGHT AA, Bohlke K, Armstrong DK, Bookman MA, et al
    Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
    Gynecol Oncol. 2016;143:3-15.
    PubMed     Text format     Abstract available


  483. KAMRAVA M
    Intensity modulated radiation therapy for women with gynecologic cancers: this horse is also already out of the barn.
    Gynecol Oncol. 2016;143:1-2.
    PubMed     Text format    


    September 2016
  484. MISHKIN G, Minasian LM, Kohn EC, Noone AM, et al
    The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies.
    Gynecol Oncol. 2016 Sep 30. pii: S0090-8258(16)31432.
    PubMed     Text format     Abstract available


  485. AL-NIAIMI A, Dickson EL, Albertin C, Karnowski J, et al
    The impact of perioperative beta blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
    Gynecol Oncol. 2016 Sep 29. pii: S0090-8258(16)31425.
    PubMed     Text format     Abstract available


  486. MUELLER JJ, Kelly A, Zhou Q, Iasonos A, et al
    Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
    Gynecol Oncol. 2016 Sep 28. pii: S0090-8258(16)31420.
    PubMed     Text format     Abstract available


  487. ROSE PG, Java JJ, Morgan MA, Alvarez-Secord A, et al
    Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2016 Sep 27. pii: S0090-8258(16)31368.
    PubMed     Text format     Abstract available


  488. ARMBRUSTER SD, Song J, Bradford A, Carmack CL, et al
    Sexual health of endometrial cancer survivors before and after a physical activity intervention: A retrospective cohort analysis.
    Gynecol Oncol. 2016 Sep 24. pii: S0090-8258(16)31422.
    PubMed     Text format     Abstract available


  489. OH J, Barve M, Matthews CM, Koon EC, et al
    Phase II study of Vigil(R) DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
    Gynecol Oncol. 2016 Sep 24. pii: S0090-8258(16)31424.
    PubMed     Text format     Abstract available


  490. WHITE ID, Sangha A, Lucas G, Wiseman T, et al
    Assessment of sexual difficulties associated with multi-modal treatment for cervical or endometrial cancer: A systematic review of measurement instruments.
    Gynecol Oncol. 2016 Sep 23. pii: S0090-8258(16)31359.
    PubMed     Text format     Abstract available


  491. FU Y, Biglia N, Wang Z, Shen Y, et al
    Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer.
    Gynecol Oncol. 2016 Sep 23. pii: S0090-8258(16)31427.
    PubMed     Text format     Abstract available


  492. WILBUR MB, Mannschreck DB, Angarita AM, Matsuno RK, et al
    Unplanned 30-day hospital readmission as a quality measure in gynecologic oncology.
    Gynecol Oncol. 2016 Sep 21. pii: S0090-8258(16)31426.
    PubMed     Text format     Abstract available


  493. CAMPBELL G, Hagan T, Gilbertson-White S, Houze M, et al
    Cancer and treatment-related symptoms are associated with mobility disability in women with ovarian cancer: A cross-sectional study.
    Gynecol Oncol. 2016 Sep 18. pii: S0090-8258(16)31414.
    PubMed     Text format     Abstract available


  494. STECKLEIN SR, Jhingran A, Burzawa J, Ramalingam P, et al
    Patterns of recurrence and survival in neuroendocrine cervical cancer.
    Gynecol Oncol. 2016 Sep 16. pii: S0090-8258(16)31409.
    PubMed     Text format     Abstract available


  495. BRAGA A, Torres B, Burla M, Maesta I, et al
    Is chemotherapy necessary for patients with molar pregnancy and human chorionic gonadotropin serum levels raised but falling at 6months after uterine evacuation?
    Gynecol Oncol. 2016 Sep 15. pii: S0090-8258(16)31413.
    PubMed     Text format     Abstract available


  496. ROBIN TP, Amini A, Schefter TE, Behbakht K, et al
    Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer.
    Gynecol Oncol. 2016 Sep 15. pii: S0090-8258(16)31412.
    PubMed     Text format     Abstract available


  497. COWAN RA, Suidan RS, Andikyan V, Rezk YA, et al
    Electronic patient-reported outcomes from home in patients recovering from major gynecologic cancer surgery: A prospective study measuring symptoms and health-related quality of life.
    Gynecol Oncol. 2016 Sep 13. pii: S0090-8258(16)31362.
    PubMed     Text format     Abstract available


  498. KATO K, Nomura H, Nagashima M, Takeshima N, et al
    Secondary debulking surgery for isolated pelvic nodal recurrence requiring external iliac vein excision and reconstruction in a patient with ovarian cancer.
    Gynecol Oncol. 2016 Sep 11. pii: S0090-8258(16)31411.
    PubMed     Text format     Abstract available


  499. HOGEN L, Thomas G, Bernardini M, Bassiouny D, et al
    The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma.
    Gynecol Oncol. 2016 Sep 9. pii: S0090-8258(16)31369.
    PubMed     Text format     Abstract available


  500. PINSKY PF, Yu K, Kramer BS, Black A, et al
    Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.
    Gynecol Oncol. 2016 Sep 8. pii: S0090-8258(16)31361.
    PubMed     Text format     Abstract available


  501. SINGH S, Guetzko M, Resnick K
    Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2016 Sep 8. pii: S0090-8258(16)31367.
    PubMed     Text format     Abstract available


  502. ALHILLI MM, Becker MA, Weroha SJ, Flatten KS, et al
    In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
    Gynecol Oncol. 2016 Sep 7. pii: S0090-8258(16)31355.
    PubMed     Text format     Abstract available


  503. MELAMED A, Hinchcliff EM, Clemmer JT, Bregar AJ, et al
    Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States.
    Gynecol Oncol. 2016 Sep 6. pii: S0090-8258(16)31365.
    PubMed     Text format     Abstract available


  504. NAKAYAMA M, Kobayashi H, Takahara T, Nishimura Y, et al
    A comparison of overall survival with 40 and 50mg/m2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data.
    Gynecol Oncol. 2016 Sep 6. pii: S0090-8258(16)31357.
    PubMed     Text format     Abstract available


  505. MANGILI G, Ottolina J, Cormio G, Loizzi V, et al
    Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study.
    Gynecol Oncol. 2016 Sep 3. pii: S0090-8258(16)31342.
    PubMed     Text format     Abstract available


  506. SAWAYA GF
    Cervical cancer screening in women over 65. CON: Reasons for uncertainty.
    Gynecol Oncol. 2016;142:383-4.
    PubMed     Text format    


  507. WAN YL, Beverley-Stevenson R, Carlisle D, Clarke S, et al
    Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions.
    Gynecol Oncol. 2016 Sep 1. pii: S0090-8258(16)31360.
    PubMed     Text format     Abstract available


    August 2016
  508. NASSER S, Lazaridis A, Evangelou M, Jones B, et al
    Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: A retrospective evaluation.
    Gynecol Oncol. 2016 Aug 29. pii: S0090-8258(16)31348.
    PubMed     Text format     Abstract available


  509. KALDAWY A, Segev Y, Lavie O, Auslender R, et al
    Low-grade serous ovarian cancer: A review.
    Gynecol Oncol. 2016 Aug 28. pii: S0090-8258(16)31346.
    PubMed     Text format     Abstract available


  510. CAMPOS-PARRA AD, Padua-Bracho A, Pedroza-Torres A, Figueroa-Gonzalez G, et al
    Comprehensive transcriptome analysis identifies pathways with therapeutic potential in locally advanced cervical cancer.
    Gynecol Oncol. 2016 Aug 28. pii: S0090-8258(16)31353.
    PubMed     Text format     Abstract available


  511. CASS I, Duska LR, Blank SV, Cheng G, et al
    Stress and burnout among gynecologic oncologists: A Society of Gynecologic Oncology Evidence-based Review and Recommendations.
    Gynecol Oncol. 2016 Aug 27. pii: S0090-8258(16)31345.
    PubMed     Text format    


  512. MORSE CB, Norquist BM, Harrell MI, Agnew KJ, et al
    Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2016 Aug 27. pii: S0090-8258(16)31351.
    PubMed     Text format     Abstract available


  513. BRIGHTWELL RM, Grzankowski KS, Lele S, Eng K, et al
    The CD47 "don't eat me signal" is highly expressed in human ovarian cancer.
    Gynecol Oncol. 2016 Aug 25. pii: S0090-8258(16)31352.
    PubMed     Text format     Abstract available


  514. GERSHENSON DM, Frazier AL
    Conundrums in the management of malignant ovarian germ cell tumors: Toward lessening acute morbidity and late effects of treatment.
    Gynecol Oncol. 2016 Aug 25. pii: S0090-8258(16)31354.
    PubMed     Text format     Abstract available


  515. SINNO AK, Peijnenburg E, Fader AN, Temkin SM, et al
    Reducing overtreatment: A comparison of lymph node assessment strategies for endometrial cancer.
    Gynecol Oncol. 2016 Aug 24. pii: S0090-8258(16)31349.
    PubMed     Text format     Abstract available


  516. PAIK ES, Shim M, Choi HJ, Lee YY, et al
    Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis.
    Gynecol Oncol. 2016 Aug 23. pii: S0090-8258(16)31347.
    PubMed     Text format     Abstract available


  517. RASMUSSEN CB, Jensen A, Albieri V, Andersen KK, et al
    Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: A nationwide population-based cohort study.
    Gynecol Oncol. 2016 Aug 20. pii: S0090-8258(16)31344.
    PubMed     Text format     Abstract available


  518. MONK BJ, Poveda A, Vergote I, Raspagliesi F, et al
    Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
    Gynecol Oncol. 2016 Aug 18. pii: S0090-8258(16)30983.
    PubMed     Text format     Abstract available


  519. ESCOBAR PF, Ramirez PT, Garcia Ocasio RE, Pareja R, et al
    Utility of indocyanine green (ICG) intra-operative angiography to determine uterine vascular perfusion at the time of radical trachelectomy.
    Gynecol Oncol. 2016 Aug 17. pii: S0090-8258(16)31262.
    PubMed     Text format     Abstract available


  520. MOORE KN, Java JJ, Slaughter KN, Rose PG, et al
    Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.
    Gynecol Oncol. 2016 Aug 16. pii: S0090-8258(16)31343.
    PubMed     Text format     Abstract available


  521. UPPAL S, Rice LW, Beniwal A, Spencer RJ, et al
    Trends in hospice discharge, documented inpatient palliative care services and inpatient mortality in ovarian carcinoma.
    Gynecol Oncol. 2016 Aug 16. pii: S0090-8258(16)31261.
    PubMed     Text format     Abstract available


  522. PEDERSEN K, Burger EA, Sy S, Kristiansen IS, et al
    Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing.
    Gynecol Oncol. 2016 Aug 16. pii: S0090-8258(16)31254.
    PubMed     Text format     Abstract available


  523. SMITH B, Neff R, Cohn DE, Backes FJ, et al
    The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role.
    Gynecol Oncol. 2016 Aug 15. pii: S0090-8258(16)31260.
    PubMed     Text format     Abstract available


  524. HAY CM, Courtney-Brooks M, Lefkowits C, Hagan TL, et al
    Symptom management in women with recurrent ovarian cancer: Do patients and clinicians agree on what symptoms are most important?
    Gynecol Oncol. 2016 Aug 13. pii: S0090-8258(16)31258.
    PubMed     Text format     Abstract available


  525. BEAVIS AL, Salazar-Marioni S, Sinno AK, Stone RL, et al
    Sentinel lymph node detection rates using indocyanine green in women with early-stage cervical cancer.
    Gynecol Oncol. 2016 Aug 12. pii: S0090-8258(16)31259.
    PubMed     Text format     Abstract available


  526. RENDON GJ, Echeverri L, Echeverri F, Sanz-Lomana CM, et al
    Outpatient laparoscopic nerve-sparing radical hysterectomy: A feasibility study and analysis of perioperative outcomes.
    Gynecol Oncol. 2016 Aug 9. pii: S0090-8258(16)31256.
    PubMed     Text format     Abstract available


  527. TOZZI R, Traill Z, Garruto Campanile R, Ferrari F, et al
    Porta hepatis peritonectomy and hepato-celiac lymphadenectomy in patients with stage IIIC-IV ovarian cancer: Diagnostic pathway, surgical technique and outcomes.
    Gynecol Oncol. 2016 Aug 9. pii: S0090-8258(16)31255.
    PubMed     Text format     Abstract available


  528. SMITH HJ, Pasko DN, Haygood CL, Boone JD, et al
    Early warning score: An indicator of adverse outcomes in postoperative patients on a gynecologic oncology service.
    Gynecol Oncol. 2016 Aug 6. pii: S0090-8258(16)31141.
    PubMed     Text format     Abstract available


  529. CHAO A, Wu RC, Jung SM, Lee YS, et al
    Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology.
    Gynecol Oncol. 2016 Aug 4. pii: S0090-8258(16)30985.
    PubMed     Text format     Abstract available


  530. LOPEZ-RUIZ ME, Diestro MD, Yebenes L, Berjon A, et al
    One-step nucleic acid amplification (OSNA) for the detection of sentinel lymph node metastasis in endometrial cancer.
    Gynecol Oncol. 2016 Aug 3. pii: S0090-8258(16)30977.
    PubMed     Text format     Abstract available


  531. SCHLAPPE BA, Mueller JJ, Zivanovic O, Gardner GJ, et al
    Corrigendum to "Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center" [Gynecol. Oncol. 142 (2016) 13-1
    Gynecol Oncol. 2016 Aug 2. pii: S0090-8258(16)30966.
    PubMed     Text format    


  532. ALETTI GD, Cliby WA
    Time for centralizing patients with ovarian cancer: what are we waiting for?
    Gynecol Oncol. 2016;142:209-10.
    PubMed     Text format    


    July 2016
  533. SHIH KK, Hajj C, Kollmeier M, Frey MK, et al
    Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy.
    Gynecol Oncol. 2016 Jul 30. pii: S0090-8258(16)30987.
    PubMed     Text format     Abstract available


  534. MELAMED A, Gockley AA, Joseph NT, Sun SY, et al
    Effect of race/ethnicity on risk of complete and partial molar pregnancy after adjustment for age.
    Gynecol Oncol. 2016 Jul 30. pii: S0090-8258(16)30988.
    PubMed     Text format     Abstract available


  535. BOGANI G, Fuca G, Maltese G, Ditto A, et al
    Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2016 Jul 29. pii: S0090-8258(16)30981.
    PubMed     Text format     Abstract available


  536. FRUMOVITZ M, Burzawa JK, Byers LA, Lyons YA, et al
    Corrigendum to "Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer" [Gynecol. Oncol. 141 (2016) 588-591].
    Gynecol Oncol. 2016 Jul 28. pii: S0090-8258(16)30979.
    PubMed     Text format    


  537. NAHAS S, Feigenberg T, Park S
    Feasibility and safety of same-day discharge after minimally invasive hysterectomy in gynecologic oncology: A systematic review of the literature.
    Gynecol Oncol. 2016 Jul 27. pii: S0090-8258(16)30984.
    PubMed     Text format     Abstract available


  538. WANG Y, Gao C, Zhang Y, Gao J, et al
    Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.
    Gynecol Oncol. 2016 Jul 26. pii: S0090-8258(16)30980.
    PubMed     Text format     Abstract available


  539. FADER AN, Habermann EB, Hanson KT, Lin JF, et al
    Disparities in treatment and survival for women with endometrial cancer: A contemporary national cancer database registry analysis.
    Gynecol Oncol. 2016 Jul 25. pii: S0090-8258(16)30978.
    PubMed     Text format     Abstract available


  540. SANTOIEMMA PP, Reyes C, Wang LP, McLane MW, et al
    Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer.
    Gynecol Oncol. 2016 Jul 25. pii: S0090-8258(16)30976.
    PubMed     Text format     Abstract available


  541. PETRICONE-WESTWOOD D, Lebel S
    Being a caregiver to patients with ovarian cancer: A scoping review of the literature.
    Gynecol Oncol. 2016 Jul 24. pii: S0090-8258(16)30876.
    PubMed     Text format     Abstract available


  542. KANSKA J, Zakhour M, Taylor-Harding B, Karlan BY, et al
    Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.
    Gynecol Oncol. 2016 Jul 23. pii: S0090-8258(16)30982.
    PubMed     Text format     Abstract available


  543. WILSON AJ, Sarfo-Kantanka K, Barrack T, Steck A, et al
    Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
    Gynecol Oncol. 2016 Jul 19. pii: S0090-8258(16)30957.
    PubMed     Text format     Abstract available


  544. TOZZI R, Gubbala K, Majd HS, Campanile RG, et al
    Interval Laparoscopic En-Bloc Resection of the Pelvis (L-EnBRP) in patients with stage IIIC-IV ovarian cancer: Description of the technique and surgical outcomes.
    Gynecol Oncol. 2016 Jul 19. pii: S0090-8258(16)30837.
    PubMed     Text format     Abstract available


  545. GAO B, Lindemann K, Anderson L, Fereday S, et al
    Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.
    Gynecol Oncol. 2016 Jul 18. pii: S0090-8258(16)30834.
    PubMed     Text format     Abstract available


  546. BROWN AJ, Shen MJ, Urbauer D, Taylor J, et al
    Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients.
    Gynecol Oncol. 2016 Jul 18. pii: S0090-8258(16)30879.
    PubMed     Text format     Abstract available


  547. MOGENSEN JB, Kjaer SK, Mellemkjaer L, Jensen A, et al
    Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study.
    Gynecol Oncol. 2016 Jul 15. pii: S0090-8258(16)30964.
    PubMed     Text format     Abstract available


  548. DONOYAMA N, Satoh T, Hamano T, Ohkoshi N, et al
    Physical effects of Anma therapy (Japanese massage) for gynecologic cancer survivors: A randomized controlled trial.
    Gynecol Oncol. 2016 Jul 15. pii: S0090-8258(16)30833.
    PubMed     Text format     Abstract available


  549. WANG D, Li C, Zhang Y, Wang M, et al
    Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Gynecol Oncol. 2016 Jul 14. pii: S0090-8258(16)30961.
    PubMed     Text format     Abstract available


  550. YANG J, Xiang Y, Wan X, Feng F, et al
    Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): A report based on our 10-year clinical experiences.
    Gynecol Oncol. 2016 Jul 14. pii: S0090-8258(16)30970.
    PubMed     Text format     Abstract available


  551. GUNDERSON CC, Ding K, Dvorak J, Moore KN, et al
    The pro-inflammatory effect of obesity on high grade serous ovarian cancer.
    Gynecol Oncol. 2016 Jul 14. pii: S0090-8258(16)30972.
    PubMed     Text format     Abstract available


  552. KONG TW, Lee JD, Son JH, Paek J, et al
    Treatment outcomes in patients with FIGO stage IB-IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: A propensity score matching study.
    Gynecol Oncol. 2016 Jul 14. pii: S0090-8258(16)30969.
    PubMed     Text format     Abstract available


  553. PEDROZA-TORRES A, Fernandez-Retana J, Peralta-Zaragoza O, Jacobo-Herrera N, et al
    A microRNA expression signature for clinical response in locally advanced cervical cancer.
    Gynecol Oncol. 2016 Jul 13. pii: S0090-8258(16)30962.
    PubMed     Text format     Abstract available


  554. SOARES RR, Maesta I, Colon J, Braga A, et al
    Complete molar pregnancy in adolescents from North and South America: Clinical presentation and risk of gestational trophoblastic neoplasia.
    Gynecol Oncol. 2016 Jul 13. pii: S0090-8258(16)30836.
    PubMed     Text format     Abstract available


  555. CHAN JK, Gardner AB, Chan JE, Guan A, et al
    The influence of age and other prognostic factors associated with survival of ovarian immature teratoma - A study of 1307 patients.
    Gynecol Oncol. 2016 Jul 13. pii: S0090-8258(16)30835.
    PubMed     Text format     Abstract available


  556. TALHOUK A, Hoang LN, McConechy MK, Nakonechny Q, et al
    Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment.
    Gynecol Oncol. 2016 Jul 13. pii: S0090-8258(16)30959.
    PubMed     Text format     Abstract available


  557. CIBULA D, Zikan M, Slama J, Fischerova D, et al
    Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer.
    Gynecol Oncol. 2016 Jul 12. pii: S0090-8258(16)30968.
    PubMed     Text format     Abstract available


  558. WONG AT, Rineer J, Lee YC, Schwartz D, et al
    Utilization of adjuvant therapies and their impact on survival for women with stage IIIC endometrial adenocarcinoma.
    Gynecol Oncol. 2016 Jul 12. pii: S0090-8258(16)30960.
    PubMed     Text format     Abstract available


  559. WATSON CH, Ulm M, Blackburn P, Smiley L, et al
    Video-assisted genetic counseling in patients with ovarian, fallopian and peritoneal carcinoma.
    Gynecol Oncol. 2016 Jul 11. pii: S0090-8258(16)30963.
    PubMed     Text format     Abstract available


  560. DE LA MOTTE ROUGE T, Pautier P, Genestie C, Rey A, et al
    Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.
    Gynecol Oncol. 2016 Jul 8. pii: S0090-8258(16)30862.
    PubMed     Text format     Abstract available


  561. SLAMA J, Cerny A, Dusek L, Fischerova D, et al
    Results of less radical fertility-sparing procedures with omitted parametrectomy for cervical cancer: 5years of experience.
    Gynecol Oncol. 2016 Jul 7. pii: S0090-8258(16)30877.
    PubMed     Text format     Abstract available


  562. MARTIN JY, Goff BA, Urban RR
    Preoperative hyponatremia in women with ovarian cancer: An additional cause for concern?
    Gynecol Oncol. 2016 Jul 4. pii: S0090-8258(16)30829.
    PubMed     Text format     Abstract available


  563. ROSENBLATT KA, Osterbur EF, Douglas JA
    Case-control study of cervical cancer and gynecologic screening: A SEER-Medicare analysis.
    Gynecol Oncol. 2016 Jul 4. pii: S0090-8258(16)30827.
    PubMed     Text format     Abstract available


  564. GIANNAKEAS V, Sopik V, Narod SA
    A model for ovarian cancer progression based on inherent resistance.
    Gynecol Oncol. 2016 Jul 4. pii: S0090-8258(16)30825.
    PubMed     Text format     Abstract available


  565. WALKER JL
    Intraperitoneal chemotherapy for ovarian cancer.
    Gynecol Oncol. 2016;142:1-2.
    PubMed     Text format    


    June 2016
  566. SZUBERT S, Wojtowicz A, Moszynski R, Zywica P, et al
    External validation of the IOTA ADNEX model performed by two independent gynecologic centers.
    Gynecol Oncol. 2016 Jun 30. pii: S0090-8258(16)30831.
    PubMed     Text format     Abstract available


  567. DE LEON M, Cardenas H, Vieth E, Emerson R, et al
    Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
    Gynecol Oncol. 2016 Jun 30. pii: S0090-8258(16)30828.
    PubMed     Text format     Abstract available


  568. MATSUO K, Moeini A, Machida H, Fullerton ME, et al
    Significance of venous thromboembolism in women with cervical cancer.
    Gynecol Oncol. 2016 Jun 24. pii: S0090-8258(16)30817.
    PubMed     Text format     Abstract available


  569. ATASEVEN B, Chiva LM, Harter P, Gonzalez-Martin A, et al
    FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited.
    Gynecol Oncol. 2016 Jun 19. pii: S0090-8258(16)30824.
    PubMed     Text format     Abstract available


  570. RAUH-HAIN JA, Birrer M, Del Carmen MG
    "Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities".
    Gynecol Oncol. 2016 Jun 16. pii: S0090-8258(16)30771.
    PubMed     Text format     Abstract available


  571. BARBER EL, Bensen JT, Snavely AC, Gehrig PA, et al
    Who presents satisfied? Non-modifiable factors associated with patient satisfaction among gynecologic oncology clinic patients.
    Gynecol Oncol. 2016 Jun 10. pii: S0090-8258(16)30814.
    PubMed     Text format     Abstract available


  572. ROQUE DR, Makowski L, Chen TH, Rashid N, et al
    Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project.
    Gynecol Oncol. 2016 Jun 8. pii: S0090-8258(16)30811.
    PubMed     Text format     Abstract available


  573. LEE J, Aphinyanaphongs Y, Curtin JP, Chern JY, et al
    The safety of same-day discharge after laparoscopic hysterectomy for endometrial cancer.
    Gynecol Oncol. 2016 Jun 8. pii: S0090-8258(16)30815.
    PubMed     Text format     Abstract available


  574. ANDRIKOPOULOU M, Vetere P, Nezhat FR
    Ovarian cancer laparoscopic hysterectomy and staging in a patient with history of intraperitoneal renal transplant.
    Gynecol Oncol. 2016 Jun 7. pii: S0090-8258(16)30812.
    PubMed     Text format     Abstract available


  575. HIJAZ M, Chhina J, Mert I, Taylor M, et al
    Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Gynecol Oncol. 2016 Jun 6. pii: S0090-8258(16)30773.
    PubMed     Text format     Abstract available


  576. IMAI K, Kato H, Katayama K, Nakanishi K, et al
    A preoperative risk-scoring system to predict lymph node metastasis in endometrial cancer and stratify patients for lymphadenectomy.
    Gynecol Oncol. 2016 Jun 4. pii: S0090-8258(16)30772.
    PubMed     Text format     Abstract available


  577. TSENG JH, Suidan RS, Zivanovic O, Gardner GJ, et al
    Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes.
    Gynecol Oncol. 2016 Jun 4. pii: S0090-8258(16)30764.
    PubMed     Text format     Abstract available


  578. FREEMAN AH, Barrie A, Lyon L, Littell RD, et al
    Venous thromboembolism following minimally invasive surgery among women with endometrial cancer.
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30770.
    PubMed     Text format     Abstract available


  579. SAWYER BT, LaFargue CJ, Bristow RE
    Extended left upper quadrant resection during primary cytoreductive surgery for Stage IV ovarian cancer.
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30769.
    PubMed     Text format     Abstract available


  580. BARBER EL, Rutstein SE, Miller WC, Gehrig PA, et al
    Corrigendum to 'A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery' Gynecol. Oncol. 139 (2015) start 401-406.
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30767.
    PubMed     Text format    


  581. ESSELEN KM, Terry KL, Samuel A, Elias KM, et al
    Endosalpingiosis: More than just an incidental finding at the time of gynecologic surgery?
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30765.
    PubMed     Text format     Abstract available


  582. JHINGRAN A, Klopp A
    Big Data to the Rescue: Is there a benefit to combined-modality adjuvant therapy in endometrial cancer?
    Gynecol Oncol. 2016;141:403-4.
    PubMed     Text format    


  583. CRONIN B, Bregar A, Luis C, Schechter S, et al
    Evaluation of anal cytology and dysplasia in women with a history of lower genital tract dysplasia and malignancy.
    Gynecol Oncol. 2016;141:492-6.
    PubMed     Text format     Abstract available


  584. ORTON A, Boothe D, Williams N, Buchmiller T, et al
    Brachytherapy improves survival in primary vaginal cancer.
    Gynecol Oncol. 2016;141:501-6.
    PubMed     Text format     Abstract available


  585. WRIGHT JD, Chen L, Jorge S, Burke WM, et al
    Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery.
    Gynecol Oncol. 2016;141:531-7.
    PubMed     Text format     Abstract available


  586. HODEIB M, Cohen JG, Mehta S, Rimel BJ, et al
    Recurrence and risk of progression to lower genital tract malignancy in women with high grade VAIN.
    Gynecol Oncol. 2016;141:507-10.
    PubMed     Text format     Abstract available


  587. LI J, Wang Z, Chen C, Liu P, et al
    Distribution of iliac veins posterior to the common iliac artery bifurcation related to pelvic lymphadenectomy: A digital in vivo anatomical study of 442 Chinese females.
    Gynecol Oncol. 2016;141:538-42.
    PubMed     Text format     Abstract available


    May 2016
  588. NEAL SA, Graybill WS, Garrett-Mayer E, McDowell ML, et al
    Lymph-vascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases?
    Gynecol Oncol. 2016 May 31. pii: S0090-8258(16)30766.
    PubMed     Text format     Abstract available


  589. ZHAO S, Sebire NJ, Kaur B, Seckl MJ, et al
    Molecular genotyping of placental site and epithelioid trophoblastic tumours; female predominance.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30761.
    PubMed     Text format     Abstract available


  590. GOUY S, Ferron G, Glehen O, Bayar A, et al
    Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30760.
    PubMed     Text format     Abstract available


  591. BROWN AJ, Shah JS, Fleming ND, Nick AM, et al
    Role of cervical cytology in surveillance after radical trachelectomy for cervical cancer.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30762.
    PubMed     Text format     Abstract available


  592. ROSSI A, Garber CE, Ortiz M, Viswanathan S, et al
    Feasibility of a physical activity intervention for obese, socioculturally diverse endometrial cancer survivors.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30763.
    PubMed     Text format     Abstract available


  593. HERNANDEZ L, Kim MK, Lyle LT, Bunch KP, et al
    Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30757.
    PubMed     Text format     Abstract available


  594. UPPAL S, Del Carmen MG, Rice LW, Reynolds RK, et al
    Variation in care in concurrent chemotherapy administration during radiation for locally advanced cervical cancer.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30755.
    PubMed     Text format     Abstract available


  595. LIAO JB
    Immunotherapy for Gynecologic Cancers: State of the Science.
    Gynecol Oncol. 2016 May 27. pii: S0090-8258(16)30758.
    PubMed     Text format    


  596. DAHM-KAHLER P, Palmqvist C, Staf C, Holmberg E, et al
    Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - a population-based cohort study.
    Gynecol Oncol. 2016 May 26. pii: S0090-8258(16)30754.
    PubMed     Text format     Abstract available


  597. KUMAR A, Moynagh MR, Multinu F, Cliby WA, et al
    Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer.
    Gynecol Oncol. 2016 May 25. pii: S0090-8258(16)30756.
    PubMed     Text format     Abstract available


  598. JORGE S, Jones NL, Chen L, Hou JY, et al
    Characteristics, treatment and outcomes of women with immature ovarian Teratoma, 1998-2012.
    Gynecol Oncol. 2016 May 21. pii: S0090-8258(16)30753.
    PubMed     Text format     Abstract available


  599. PETRILLO M, Amadio G, Salutari V, Paris I, et al
    Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.
    Gynecol Oncol. 2016 May 20. pii: S0090-8258(16)30741.
    PubMed     Text format     Abstract available


  600. RANDALL TC, Goodman A, Schmeler K, Durfee J, et al
    Cancer and the world's poor: What's a gynecologic cancer specialist to do?
    Gynecol Oncol. 2016 May 19. pii: S0090-8258(16)30742.
    PubMed     Text format     Abstract available


  601. ATASEVEN B, Harter P, Grimm C, Heitz F, et al
    The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?
    Gynecol Oncol. 2016 May 18. pii: S0090-8258(16)30745.
    PubMed     Text format     Abstract available


  602. RAY-COQUARD I, Rizzo E, Blay JY, Casali P, et al
    Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chem
    Gynecol Oncol. 2016 May 18. pii: S0090-8258(16)30740.
    PubMed     Text format     Abstract available


  603. SLAUGHTER K, Holman LL, Thomas EL, Gunderson CC, et al
    Primary and acquired platinum-resistance among women with high grade serous ovarian cancer.
    Gynecol Oncol. 2016 May 18. pii: S0090-8258(16)30744.
    PubMed     Text format     Abstract available


  604. DAI D, Thiel KW, Salinas EA, Goodheart MJ, et al
    Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations.
    Gynecol Oncol. 2016 May 16. pii: S0090-8258(16)30731.
    PubMed     Text format     Abstract available


  605. POOLE EM, Konstantinopoulos PA, Terry KL
    Prognostic implications of reproductive and lifestyle factors in ovarian cancer.
    Gynecol Oncol. 2016 May 14. pii: S0090-8258(16)30733.
    PubMed     Text format     Abstract available


  606. SCHLAPPE BA, Mueller JJ, Zivanovic O, Gardner GJ, et al
    Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
    Gynecol Oncol. 2016 May 14. pii: S0090-8258(16)30734.
    PubMed     Text format     Abstract available


  607. HUSAIN A, Wang Y, Hanker LC, Ojeda B, et al
    Independent Radiologic Review of AURELIA, A Phase 3 Trial of Bevacizumab Plus Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer.
    Gynecol Oncol. 2016 May 13. pii: S0090-8258(16)30730.
    PubMed     Text format     Abstract available


  608. KONG TW, Kim J, Son JH, Kang SW, et al
    Preoperative nomogram for prediction of microscopic parametrial infiltration in patients with FIGO stage IB cervical cancer treated with radical hysterectomy.
    Gynecol Oncol. 2016 May 11. pii: S0090-8258(16)30683.
    PubMed     Text format     Abstract available


  609. ATRI M, Zhang Z, Dehdashti F, Lee SI, et al
    Utility of PET-CT to Evaluate Retroperitoneal Lymph Node Metastasis in Advanced Cervical Cancer: Results of ACRIN6671/GOG0233 Trial.
    Gynecol Oncol. 2016 May 10. pii: S0090-8258(16)30681.
    PubMed     Text format     Abstract available


  610. KOSKAS M, Uzan J, Vanderstraeten A, Vergote I, et al
    External validation of non-imaging models for predicting distant metastasis in patients with endometrial cancer.
    Gynecol Oncol. 2016 May 9. pii: S0090-8258(16)30687.
    PubMed     Text format     Abstract available


  611. TURNER TB, Buchsbaum DJ, Straughn JM Jr, Randall TD, et al
    Ovarian cancer and the immune system - The role of targeted therapies.
    Gynecol Oncol. 2016 May 9. pii: S0090-8258(16)30686.
    PubMed     Text format     Abstract available


  612. KARLSEN NM, Karlsen MA, Hogdall E, Nedergaard L, et al
    Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT).
    Gynecol Oncol. 2016 May 7. pii: S0090-8258(16)30684.
    PubMed     Text format     Abstract available


  613. ZHAO J, Lv WG, Feng FZ, Wan XR, et al
    Placental site trophoblastic tumor: A review of 108 cases and their implications for prognosis and treatment.
    Gynecol Oncol. 2016 May 7. pii: S0090-8258(16)30685.
    PubMed     Text format     Abstract available


  614. VATANSEVER D, Atici AE, Sozen H, Sakin O, et al
    Diaphragmatic resection preserving and repairing pericardium, splenectomy and distal pancreatectomy for interval debulking surgery of ovarian cancer.
    Gynecol Oncol. 2016 May 7. pii: S0090-8258(16)30682.
    PubMed     Text format     Abstract available


  615. CRAFTON SM, Bixel K, Hays JL
    PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.
    Gynecol Oncol. 2016 May 7. pii: S0090-8258(16)30680.
    PubMed     Text format     Abstract available


  616. XIONG J, He M, Hansen K, Jackson CL, et al
    The clinical significance of K-ras mutation in endometrial "surface epithelial changes" and their associated endometrial adenocarcinoma.
    Gynecol Oncol. 2016 May 3. pii: S0090-8258(16)30679.
    PubMed     Text format     Abstract available


  617. ZHANG D, Bai B, Xi Y, Wang T, et al
    Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis.
    Gynecol Oncol. 2016 May 2. pii: S0090-8258(16)30677.
    PubMed     Text format     Abstract available


  618. LESTER-COLL NH, Park HS, Rutter CE, Corso CD, et al
    Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base.
    Gynecol Oncol. 2016 May 2. pii: S0090-8258(16)30678.
    PubMed     Text format     Abstract available


  619. WOLFSON AH, Reis IM, Portelance L, Diaz DA, et al
    Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer: A SEER analysis.
    Gynecol Oncol. 2016;141:255-9.
    PubMed     Text format     Abstract available


    April 2016
  620. STROHL AE, Feinglass JM, Shahabi S, Simon MA, et al
    Surgical wait time: A new health indicator in women with endometrial cancer.
    Gynecol Oncol. 2016 Apr 22. pii: S0090-8258(16)30146.
    PubMed     Text format     Abstract available


  621. RODRIGUEZ GC, Turbov J, Rosales R, Yoo J, et al
    Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: An opportunity for chemoprevention.
    Gynecol Oncol. 2016 Apr 19. pii: S0090-8258(16)30154.
    PubMed     Text format     Abstract available


  622. FENG Z, Wen H, Bi R, Yang W, et al
    Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer.
    Gynecol Oncol. 2016 Apr 17. pii: S0090-8258(16)30148.
    PubMed     Text format     Abstract available


  623. NAROD SA
    Talc and ovarian cancer.
    Gynecol Oncol. 2016 Apr 16. pii: S0090-8258(16)30139.
    PubMed     Text format    


  624. EGGINK FA, Mom CH, Kruitwagen RF, Reyners AK, et al
    Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands.
    Gynecol Oncol. 2016 Apr 15. pii: S0090-8258(16)30140.
    PubMed     Text format     Abstract available


  625. FRUMOVITZ M, Burzawa JK, Byers LA, Lyons YA, et al
    Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer.
    Gynecol Oncol. 2016 Apr 11. pii: S0090-8258(16)30102.
    PubMed     Text format     Abstract available


  626. KOBEL M, Atenafu EG, Rambau PF, Ferguson SE, et al
    Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
    Gynecol Oncol. 2016 Apr 9. pii: S0090-8258(16)30109.
    PubMed     Text format     Abstract available


  627. ZHOU Y, Irwin ML, Ferrucci LM, McCorkle R, et al
    Health-related quality of life in ovarian cancer survivors: Results from the American Cancer Society's Study of Cancer Survivors - I.
    Gynecol Oncol. 2016 Apr 9. pii: S0090-8258(16)30106.
    PubMed     Text format     Abstract available


  628. CLARK LH, Jackson AL, Soo AE, Orrey DC, et al
    Extremes in body mass index affect overall survival in women with cervical cancer.
    Gynecol Oncol. 2016 Apr 4. pii: S0090-8258(16)30091.
    PubMed     Text format     Abstract available


  629. NOER MC, Sperling CD, Antonsen SL, Ottesen B, et al
    A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients.
    Gynecol Oncol. 2016 Apr 4. pii: S0090-8258(16)30090.
    PubMed     Text format     Abstract available


  630. ALVAREZ RD, Matulonis UA, Herzog TJ, Coleman RL, et al
    Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.
    Gynecol Oncol. 2016 Apr 3. pii: S0090-8258(16)30063.
    PubMed     Text format    


  631. MUNKARAH A, Mert I, Chhina J, Hamid S, et al
    Targeting of free fatty acid receptor 1 in EOC: A novel strategy to restrict the adipocyte-EOC dependence.
    Gynecol Oncol. 2016;141:72-9.
    PubMed     Text format     Abstract available


  632. ROMA AA, Mistretta TA, Diaz De Vivar A, Park KJ, et al
    New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome.
    Gynecol Oncol. 2016;141:36-42.
    PubMed     Text format     Abstract available


  633. KYRGIOU M, Pouliakis A, Panayiotides JG, Margari N, et al
    Personalised management of women with cervical abnormalities using a clinical decision support scoring system.
    Gynecol Oncol. 2016;141:29-35.
    PubMed     Text format     Abstract available


  634. JANCO JM, Kumar A, Weaver AL, McGree ME, et al
    Performance of AGO score for secondary cytoreduction in a high-volume U.S. center.
    Gynecol Oncol. 2016;141:140-7.
    PubMed     Text format     Abstract available


    March 2016
  635. MANLEY KM, Wills AK, Morris GC, Hogg JL, et al
    The impact of HPV cervical screening on negative large loop excision of the transformation zone (LLETZ): A comparative cohort study.
    Gynecol Oncol. 2016 Mar 28. pii: S0090-8258(16)30088.
    PubMed     Text format     Abstract available


  636. HOLST S, Wohlfahrt J, Kjaer SK, Kamper-Jorgensen M, et al
    Cervical cancer screening in Greenland, 1997-2011: Screening coverage and trends in the incidence of high-grade cervical lesions.
    Gynecol Oncol. 2016 Mar 23. pii: S0090-8258(16)30085.
    PubMed     Text format     Abstract available


  637. BACKES FJ, Fowler JM
    Late side effects of robotic surgery.
    Gynecol Oncol. 2016;140:375-6.
    PubMed     Text format    


  638. VAN DOORN HC, van Beekhuizen HJ, Gaarenstroom KN, van der Velden J, et al
    Repeat sentinel lymph node procedure in patients with recurrent vulvar squamous cell carcinoma is feasible.
    Gynecol Oncol. 2016;140:415-9.
    PubMed     Text format     Abstract available


  639. ROBERTSON NL, Hricak H, Sonoda Y, Sosa RE, et al
    The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.
    Gynecol Oncol. 2016;140:420-4.
    PubMed     Text format     Abstract available


    February 2016
  640. NAROD SA, Sopik V, Giannakeas V
    Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial.
    Gynecol Oncol. 2016 Feb 25. pii: S0090-8258(16)30044.
    PubMed     Text format    


  641. BRADFORD A, Shinn E
    Incorporating Patient Perspectives and Priorities into Clinical Trial Design.
    Gynecol Oncol. 2016;140:191-2.
    PubMed     Text format    


  642. ALVAREZ RD, Huh WK, Bae S, Lamb LS Jr, et al
    A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).
    Gynecol Oncol. 2016;140:245-52.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: